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A B S T R A C T
Background
In acute asthma inhaled β2-agonists are often administered to relieve bronchospasm by wet nebulisation, but some have argued that
metered-dose inhalers with a holding chamber (spacer) can be equally effective. Nebulisers require a power source and need regular
maintenance, and are more expensive in the community setting.
Objectives
To assess the effects of holding chambers (spacers) compared to nebulisers for the delivery of ß2-agonists for acute asthma.
Search methods
We searched the Cochrane Airways Group Trial Register and reference lists of articles. We contacted the authors of studies to identify
additional trials. Date of last search: January 2008.
Selection criteria
Randomised trials in adults and children (from two years of age) with asthma, where spacer ß2-agonist delivery was compared with
wet nebulisation.
Data collection and analysis
Two reviewers independently applied study inclusion criteria (one reviewer for the first version of the review), extracted the data and
assessed trial quality. Missing data were obtained from the authors or estimated. Results are reported with 95% confidence intervals
(CI).
Main results
This review has been updated in January 2008 and two new trials have been added. 2295 children and 614 adults are now included in
27 trials from emergency room and community settings. In addition, six trials on in-patients with acute asthma (213 children and 28
adults) have been reviewed. Method of delivery of ß2-agonist did not appear to affect hospital admission rates. In adults, the relative
risk of admission for spacer versus nebuliser was 0.97 (95% CI 0.63 to 1.49). The relative risk for children was 0.72 (95% CI: 0.47
to 1.09). In children, length of stay in the emergency department was significantly shorter when the spacer was used, with a mean
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difference of -0.53 hours (95% CI: -0.62 to -0.44 hours). Length of stay in the emergency department for adults was similar for the
two delivery methods. Peak flow and forced expiratory volume were also similar for the two delivery methods. Pulse rate was lower for
spacer in children, mean difference -6.27% baseline (95% CI: -8.29 to -4.25% baseline).
Authors’ conclusions
Metered-dose inhalers with spacer produced outcomes that were at least equivalent to nebuliser delivery. Spacers may have some
advantages compared to nebulisers for children with acute asthma.
P L A I N L A N G U A G E S U M M A R Y
Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
In acute asthma attacks higher doses of inhaled β2-agonists (reliever inhalers) are used to overcome the narrowing of the passages in
the lungs. The medication can be given by wet nebulisation or from an inhaler with a spacer device (holding chamber). This review
now includes in-patient studies, as well as those in casualty and community setting, comparing these two delivery methods in acute
asthma attacks. In adults, no important differences were found between the two methods, whilst in children those randomised to wet
nebulisation spent longer in casualty. Metered-dose inhalers with a spacer can perform at least as well as wet nebulisation in delivering
β2-agonists in acute asthma.
B A C K G R O U N D
Acute exacerbations of asthma are common and account for a con-
siderable number of physician encounters, both in hospital and in
primary care. In acute exacerbations the airways become narrowed
due to mucosal oedema, hyper secretion and bronchospasm. De-
pending on the severity of the attack, treatment with inhaled ß2-
agonists is often required in addition to other agents such as corti-
costeroids. The use of ß2-agonists is intended to relieve the bron-
chospasm. This is accomplished most effectively when the drug is
delivered to the peripheral airways. This is made more difficult in
acute asthma since the narrowed airways and faster respiratory rate
result in increased drug deposition in the throat and large airways.
Consequently, it is less effective and may cause more side effects.
Two different delivery methods have been employed to overcome
this problem: wet nebulisations and metered-dose inhalers with
a holding chamber (spacer). Nebulisation creates a mist of ß2-
agonist diluted in saline which is inhaled through a mask by tidal
breathing. Nebulisation can be accomplished with room air or
supplemental oxygen, and requires a supply of compressed gas or
a power source. More recently, ß2-agonists delivered via metered-
dose inhalers through a spacer have been used in acute asthma.
The inhaler is actuated into the spacer that is then emptied by the
patient using either tidal breathing or single breaths.
Whilst nebulisers have historically been used in acute exacerba-
tions of asthma, a meta-analysis of trials in adults with asthma
or chronic obstructive pulmonary disease (COPD) suggested
that metered-dose inhalers with a spacer are as effective (Turner
1997).There has been considerable controversy regarding themer-
its of each delivery method, but current guidelines have now
moved towards the use of spacers in acute asthma, particularly in
children (BTS 2003) . In addition, cost and infection control con-
siderations may be important additional determinants of which
system is employed. For example, in the community the cost of
nebulisers exceeds a spacer and metered-dose inhaler (MDI). In
hospital emergency departments, the cost calculations are more
complex since disposable nebulisermasks are often driven by piped
oxygen; costs may depend on whether or not all patients are sent
home with a new spacer. Nebulisers also represent a potential
source of cross-infection, and require regular maintenance. As a
result of these controversies, this systematic review has been de-
signed to assess all the available evidence from randomised con-
trolled trials comparing the two deliverymethods in acute asthma.
O B J E C T I V E S
The objective of this review was to compare the clinical outcomes
following the use of ß2-agonists in acute asthma given by two
different delivery methods: a metered-dose inhaler with spacer or
a nebuliser.
M E T H O D S
2Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were considered for this review.
Types of participants
Adults and children (but not infants) with acute asthma present-
ing for medical assistance in the community setting or hospital
emergency department. Studies describing patients who had al-
ready been admitted to hospital have been included in this up-
date. Studies on children with a mean age of two years or more
were included, as it is difficult to diagnose asthma under this age.
Studies on patients with asthma and COPDwere included as long
as separate results could be obtained for the asthma patients.
Types of interventions
Any ß2-agonist given by any nebuliser versus the same ß2-ago-
nist given by metered-dose inhaler with any spacer. The dose of
drug and method of administration must have been recorded. Co-
interventions and contamination (cross-over) may have occurred,
but these must have been recorded.
Types of outcome measures
Primary outcomes
The primary outcome measures were admission to hospital, or
duration of stay for in-patients.
Secondary outcomes
1. Duration in the emergency department






8. Use of steroids
9. Relapse rates
Search methods for identification of studies
Electronic searches
Trials were identified using the Cochrane Airways Group Spe-
cialised Register of trials, which is derived from systematic searches
of bibliographic databases including the Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), MEDLINE, EMBASE,
CINAHL, AMED and PsycINFO, and handsearching of respira-
tory journals and meeting abstracts. All records in the Specialised
Register coded as ’asthma’ were searched using the following terms:
(spacer* OR “holding chamber*” or holding-chamber* OR
volumatic OR nebuhaler* OR aerochamber* OR fisonair OR ex-
tension* OR “spacing device*” OR inspirease OR babyhaler* or
MDI or turbuhaler) AND (nebuli*)
The most recent search of the Register was carried out in January
2008.
Searching other resources
We searched the bibliographies of all included papers and reviews
for further references. We contacted authors of included studies
for identification of any unpublished or missed trials.
Data collection and analysis
Selection of studies
One reviewer (CJC) originally checked abstracts identified by the
above search and obtained the full text of publications of possibly
relevant studies, including translation when required. Trials iden-
tified for potential inclusion were independently assessed by JAC
and CJC for the 2003 and 2006 updates.
Data extraction and management
Data were extracted by CJC and checked by JAC. Authors were
sent letters asking for clarification of allocation concealment, de-
vices used, location of the patients and outcomes where these were
not clear in the original publication.
Assessment of risk of bias in included studies
We assessed the methodological quality of the included trials with
particular emphasis on the allocation concealment, which was
ranked using the Cochrane approach:
Grade A: Adequate concealment
Grade B: Uncertain
Grade C: Clearly inadequate concealment
Where there was uncertainty we contacted authors for clarifica-
tion.
We originally assessed the methodological quality of the eligible
RCTs with a five point scoring instrument, proposed by Jadad
1996. Two reviewers performed this independently. This instru-
ment evaluates the reported quality of randomisation, blinding,
and description of withdrawals and dropouts. One of the reviewers
was masked as to authors’ names and affiliation, names of journals,
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date of publication, sources of financial support for the study and
the acknowledgements. The pooled score from this instrument
has not been continued for recent updates.
Assessment of heterogeneity
Heterogeneity of the results of individual trials is shown on the
MetaView graphical displays. Where the heterogeneity exceeded
the expected 95% level, (measured using a chi squared test with
appropriate degrees of freedom), sources of heterogeneity were
explored and results were either pooled using a random effects
model, or not pooled across sub-groups.
Data synthesis
We calculated a weighted treatment effect across trials using the
Cochrane statistical package, RevMan (initially version 4.2, now
5.0). The results are expressed as relative risk (RR and 95% CI)
for dichotomous outcomes and mean difference (MD) and 95%
Confidence Interval (CI) for continuous outcomes. A fixed effect
model was used for continuous outcomes, but results using a ran-
dom effects model were also checked.
The results for adults and children have now been separated in
each outcome in view of the significant heterogeneity identified in
the pooled analyses. Furthermore it can be argued that adults and
children may differ in their ability to use the devices, their degree
of airways reversibility and in their sensitivity to side effects from
inhaled ß2-agonists.
The single treatment trials have not been pooled due to concern
over confounding due to uncertainty over the relative dose deliv-
ered and the wide range of dose-ratios used (from 1:1 to 1:13, with
the larger doses administered via nebuliser).
Sensitivity analysis
We performed sensitivity analyses on the basis of methodologi-
cal quality. The results were re-analysed using only studies of the
highest quality (scores three to five). Sensitivity analyses have also
been performed to check on the effect of estimating standard de-
viations and the data re-analysed without any estimated results.
In addition, we performed a funnel plot of hospital admissions to
check for publication bias. In view of the recent discontinuation
of Volumatic spacers in some countries, separating the trials that
used Volumatic from other types of spacer.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
112 abstracts were originally identified from the database and 44
were selected for possible inclusion in the review. For the 2006
update seven new abstracts were considered for possible inclusion.
One abstract was identified from the references in the included
studies (Hodder 1988). The full text of each paper was obtained
and translated when necessary (two from Spanish and one from
Portuguese). Papers were excluded for the following reasons: stud-
ies on non-acute asthma, different drugs delivered and no separate
data for asthma patients (see Table of Excluded Studies). A total
of 12 papers were initially included for this review and 10 fur-
ther papers were added up to 2004 (Williams 1996; Batra 1997;
Raimondi 1997;Robertson 1998;Rodrigo 1998;Rodriguez 1999;
Valencia 1999; Leversha 2000; Ploin 2000; Duarte 2002). The
2006 update includes 5 new trials (Burrows 2004;Chong-Neto
2005; Hussein 2002; Rao 2002; Vivek 2003). The latest search
was completed in January 2008, and from the 12 abstracts found,
two further trials were included (Jamalvi 2006; Sannier 2007).
Agreement between the two independent assessments of study
quality for the original review was as follows:
Randomisation: Kappa = 1
Double-blind: Kappa = 1
Withdrawals/Dropouts: Kappa = 0.8
Method of Randomisation: Kappa = 0.8
Method Blinded: Kappa = 0.5
Included studies
There are now 2295 children and 614 adults included in 27 trials
in emergency departments and the community. In addition there
are six trials incorporating 213 children and 28 adults studied after
hospital admission (Ba 1989; Burrows 2004; Coker 1995; Dewar
1999; Morley 1988; Parkin 1995).
The studies come from all over the world. Only two were car-
ried out in the community (Chong-Neto 2005;Morrone 1990);
six trials have been considered in an in-patient setting (Ba 1989;
Burrows 2004; Coker 1995; Dewar 1999; Morley 1988; Parkin
1995), and all others were conducted in hospital emergency de-
partments. The single pre-hospital study comparing nebulisation
to MDI (Campbell 1995) was excluded, as there was no randomi-
sation. Different ß2-agonists, spacers and nebulisers were repre-
sented in the studies. The dosage ratio between delivery meth-
ods varied from 1:1 to 1:13, with the larger doses administered
via nebuliser. Many recent studies used multiple treatments at
10 to 30 minute intervals(Batra 1997; Chong-Neto 2005; Chou
1995; Colacone 1993; Duarte 2002; Idris 1993; Jamalvi 2006;
Leversha 2000; Ploin 2000; Rao 2002; Rodrigo 1993; Rodrigo
1998; Sannier 2007; Valencia 1999; Vivek 2003). Most studies
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used commercially available spacers (Aerochamber, Babyhaler, In-
spirEase, Nebuhaler and Volumatic), but two studies from Brazil
(Chong-Neto 2005; Duarte 2002), used home-made spacers in
the form of a 500 ml mineral water plastic bottle. Duarte 2002
coated the bottle with detergent to avoid electrostatic charge,
whilst Chong-Neto 2005 included 10 children treated with ae-
rochamber and 10 children using a 500 ml water bottle glued onto
the MDI with Araldite. The studies using salbutamol all used the
racemic form of the drug.
In view of the proposed discontinuation of Volumatic spacers in
2005 an additional table (Table 1) has been added with details of
the type of spacer used in each study.
Excluded studies
See Characteristics of excluded studies.
Risk of bias in included studies
Overall, the methodological quality of the included studies was
variable (see Characteristics of included studies). Only four of the
included references commented on the number of participants ex-
cluded from the study. Many studies did not comment on with-
drawals and dropouts, and also did not report whether intention
to treat analysis was employed. The hospital admission rate re-
ported in one study has been amended using an intention to treat
analysis (Colacone 1993).
In general the sample size of many individual studies was small,
(range 18 to 196 participants in the emergency room studies, and
28 to 61 for in-patients). Whilst seven of the eleven studies in
adults used a double blind, double dummydesign (Colacone 1993;
Idris 1993; Rao 2002; Rodrigo 1993; Rodrigo 1998; Salzman
1989; Turner 1988) only seven of the 22 studies in children were
double-blind (Ba 1989; Chong-Neto 2005; Hussein 2002; Kerem
1993; Leversha 2000; Ploin 2000; Robertson 1998), see Figure 1.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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A funnel plot of hospital admissions did not suggest publication
bias since the smaller studies showed spread of results on both sides
of the overall relative risk (Figure 2).
Figure 2. Funnel plot of comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies),
outcome: 1.1 Hospital admission.
Effects of interventions
SPACER VERSUS NEBULISER MULTIPLE
TREATMENTS
Hospital admission rates did not differ significantly on the basis of
delivery method in adults (RR: 0.97; 95% CI: 0.63 to 1.49) or in
children (RR: 0.72; 95%CI: 0.47 to 1.09); Figure 3.No significant
heterogeneity was observed. These results did not change when
studies of lowermethodological qualitywere excluded.Two studies
in children did not report admissions but did report data on poor
outcomes (Batra 1997; Leversha 2000); when these are included
the relative risk in children of admission or poor outcome is not
significantly different between spacer and nebuliser (RR: 0.86;
95% CI: 0.60 to 1.23).
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Figure 3. Forest plot of comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies),
outcome: 1.1 Hospital admission.
Time spent in the emergency department (ED) originally showed
significant heterogeneity when the results from adults and chil-
dren were pooled, (chi squared = 8.2, df = 2, P < 0.02). This het-
erogeneity could not be explained on the basis of methodological
quality, since the result was based on trials that were all of high
methodological quality.However, no significant heterogeneity was
demonstrated when adults and children were analysed separately.
The results for adults and children have therefore been shown in
separate sub-groups in the analyses Figure 4. Duration in the ED
in children was significantly shorter with the spacer (MD -0.53
hours; 95% CI: -0.62 to -0.44). This finding is based on three
studies (Chou 1995; Duarte 2002; Sannier 2007), containing 427
participants. The fact that these were not double dummy studies
may have a bearing on these results as nebulisation is much more
time consuming than use of MDI and spacer (Duarte 2002). In
adults the duration of the ED visit was similar in both groups
(MD 0.02 hours; 95% CI: -0.4 to 0.44). Results in children and
adults are based on a fixed-effect model but are very similar when
a random-effects model is used.
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Figure 4. Forest plot of comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies),
outcome: 1.3 Duration in emergency department (hours)..
No significant differences were demonstrated between the two de-
liverymethods in terms of peak flow and forced expiratory volume
(FEV1) at 30 minutes and the end of the study. More specifically,
in the four studies in adults that included analysis of changes in
lung function in the most severely affected patients (e.g. FEV1<
30% predicted), there was no statistically significant difference be-
tween the two delivery methods (MD -1.6% predicted; 95% CI:
-7.69 to 4.49%). The only study (Maldano 1997) which found
a significant difference in FEV1 between the nebuliser and spacer
groups used a low dose of Salbutamol via the spacer (200 mcg),
and showed a significant decline in FEV1 in this group three to six
hours after the treatment was administered. This trial was not be
included in the analysis as no standard deviations were reported
and the authors did not respond to requests for further informa-
tion.
Pulse rate after treatment (expressed as % change from baseline),
was significantly lower when a spacer was used in children (MD -
6.27% baseline; 95% CI: -8.29 to -4.25%). In adults, no signifi-
cant difference was found between methods (MD -1.2% baseline;
95% CI: -4.1 to 1.6%). These results were similar for fixed and
random effects models. There was a significant difference between
the pulse changes in adults and children (Chi squared = 8.07, df
= 1, P =0.005), Figure 5.
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Figure 5. Forest plot of comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies),
outcome: 1.9 Rise in pulse rate (% baseline).
Oxygen saturation was not significantly different at the end of the
studies with a mean difference of -0.09% between groups (95%
CI: -1% to 0.8%). One study (Duarte 2002), however, reported
that 25%of children treatedwith oxygen-driven nebuliser suffered
desaturation at some point during treatment compared to 9% of
those treated with MDI and spacer (P = 0.006).
No significant differences were demonstrated between the two
delivery methods for the other measured outcomes: change in
respiratory rate and the number of participants given steroids.
Development of tremor was more common with nebuliser treat-
ment in the two studies that reported this in children, but the test
for interaction between adults and children was not significant.
No attempt has been made to combine the findings for symptom
score as the scales used were highly variable and the standard de-
viation of results were rarely reported.
In the light of the decision to temporarily withdraw Volumatic
spacers from the UK market in 2005, we carried out a post-hoc
sensitivity analysis according to whether Volumatic spacers were
used in each study. The type of spacer used is documented in Table
1 and this shows that the majority of adults and children studied
used other types of spacer. No significant differences were found
between the results from trials using Volumatic (188 adults and
364 children) and those using other types of spacer (433 adults
and 907 children). The primary outcome of hospital admission
was unaltered in children when Volumatic studies were excluded,
but the confidence intervals in adults widened; adult admission
using other spacers (RR: 1.45; 95%CI: 0.6 to 3.53) and children’s
admissions using other spacers was unchanged (RR: 0.65; 95%
CI: 0.4 to 1.06). No studies included direct comparison between
Volumatic and other types of spacer.
SPACER VERSUS NEBULISER SINGLE
TREATMENTS
Results from single treatment studies were not pooled due to con-
cern over confounding by the variable amounts of ß2-agonists de-
livered to the airways from the different delivery methods.
Blood gas results were reported in two studies (Kerem 1993; Lin
1995). The participant numbers were small but both show less
deterioration in gases with a spacer. One study (Lin 1995) also
measured lung function 15minutes after the start of treatment and
found a significantly greater rise in peak expiratory flow (PEF) at
this time with the spacer (mean difference 10.1% predicted; 95%
CI: 15.7 to 4.4%); this study is of low methodological quality,
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consequently this information should be interpreted with caution.
More recently, Hussein 2002 reported similar changes in oxygen
saturation in a single treatment study in 60 children. As yet the
author has not responded to a request for further details.
IN-PATIENT SPACER VERSUS NEBULISER
STUDIES
The primary outcome of duration of admission was available from
three studies (Morley 1988; Parkin 1995; Dewar 1999) but the
results in Dewar 1999 were skewed and presented as medians
so are not suitable for combination with the other two studies.
The duration of admission did not show a significant difference
between delivery methods, MD 0.26 hours (95% CI: -0.23 to
0.75).
The results from the individual studies have been outlined below.
Ba 1989 was a single dose comparison in children, and did not
measure the primary outcome (time to discharge). The design
was double-blind with double dummy. Continuous intravenous
aminophylline was given to all children in both groups. There was
a significant difference between groups in baseline lung function,
spacer baseline FEV1 38.2 (SD 7.9) % predicted and nebuliser
49.8 (SD 14) % predicted. Results are only presented as change
from baseline, and this will favour the spacer group. There was no
significant difference in FEV1 between groups over three hours,
and the significant advantage for the spacer in change in FVC is
probably due to baseline difference. The paper reported signifi-
cantly more children treated with spacer increased their pulse rate
at 10minutes compared to the nebuliser group, but this data could
not be used as the number of participants with increased pulse
reported in the spacer group (17) was greater than the group total
(14).
Coker 1995 was a single dose comparison in children, and did
not measure the primary outcome (time to discharge). There was
no blinding and participants were allocated by alternation. No
co-interventions were reported and no significant differences in
respiratory score or PEFwere found between groups over six hours.
Dewar 1999 compared multiple treatments in children, given up
to one hourly by each delivery method. Allocation was concealed
with sequential pre sealed envelopes and all children received oral
steroids on admission and repeated on subsequent mornings for
three to five days according to their recovery. No blinding was
reported. Data for duration of stay was noted to be skewed by
small numbers of lengthy in-patient stays so medians were used
which did not show a significant difference between groups, (36.5
hours for the spacer group and 40 hours for the nebuliser group).
Although readmission rates were lower in the spacer group, this
group were also given a written asthma plan and this may have
confounded the results for readmission and symptoms after dis-
charge. Children requiring immediate intravenous treatment were
excluded from the study, and five children were withdrawn due to
deterioration requiring intravenous treatment (three in the spacer
group and two in the nebuliser group). The authors calculated a
significant cost benefit for the spacer group in terms of drug costs,
£5.43 per patient in the spacer group and £20.25 in the nebuliser
group (P < 0.001).
Morley 1988 was the only in-patient study in adults, and used
multiple treatments. Allocation was by alternation and no blind-
ing was described. Intravenous aminophylline and methylpred-
nisolone were given at standard doses. Mean duration of hospital-
isation was not significantly different between groups, 5.8 days in
the spacer group and 6.4 days in the nebuliser group, mean differ-
ence of -0.6 days (95% CI: -3.2 to 2.0). No significant differences
were found in lung function between groups.
Parkin 1995 compared multiple treatments in younger children
(aged one to five years), but gave both salbutamol and ipratropium
by spacer or nebuliser. The research nurse only was blinded and
all children received intravenous or oral steroids. There was no
significant difference in hours to discharge (spacer 53 hours and
nebuliser 46 hours), hours to the change of treatments to four
hourly intervals or total number of inhaled doses received. Nine
participants in the spacer group crossed over to nebuliser treat-
ment, but their results were analysed by original group assignment
(intention to treat analysis).
Burrows 2004 studied 29 children aged one to six years old with
moderate to severe asthma according to BTS guidelines, who were
hospitalised between September 2003 and February 2004. No
significant differences were reported in any outcomes except for
cost (whichwas £7.68 per patient in the nebuliser group and £5.96
per patient in the spacer group). The length of stay was 16.5 hours
in the nebuliser group and 26.5 hours in the MDI and spacer
group, with change in respiratory rate of -5.4 and -6.3, change
in pulse of 2.9 and 4.6, and change in oxygen saturation of 0.53
and 1.07 for nebuliser and spacer, respectively. We have been in
communication with the author and await details of the standard
deviation of these changes to allow computation of between group
differences and confidence intervals, and pooling with the other
study results.
D I S C U S S I O N
METHODOLOGICAL LIMITATIONS
Several issues restrict the generalisability of the results of this re-
view.
(1) As patients with life threatening asthma exacerbations were
excluded from the studies (for example those patients considered
for ventilation), the results cannot be assumed to apply to this
group.
(2) Only two small studies was carried out in a community setting,
(Chong-Neto 2005; Morrone 1990). Although it is reasonable to
suppose that the findings would apply in the community setting,
further studies are required to confirm that this is the case.
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(3) Few authors reported specifically on numbers of patients pre-
senting who were excluded from each study, and intention to treat
analysis was not usually reported. Thus it is not entirely clear how
these results apply to all patients who present with an exacerba-
tion.
(4) Analysis of the data regarding lung function tests in many
papers was complicated by a lack of standardised reporting. In
addition, data regarding standard deviation related to the changes
that were measured were not always reported. Peak flow and FEV1
were the most commonly reported measurements and these were
both included in the outcome tables.
CLINICAL PRACTICE
Nebulisers are commonly used to deliver ß2-agonists in acute
asthma in the community and in hospital emergency departments.
Although spacers have also been advocated for use in these cir-
cumstances, published guidelines give few details about how they
should be used. Overall, this review supports the equivalence of
wet nebuliser and MDI with spacer administration of ß2-agonists
in the treatment of acute asthma, when treatments are repeated
and titrated to the response of the patient. This review also sug-
gests that paediatric patients given ß2-agonists by spacer andMDI
may have shorter stays in the ED, less hypoxia, and lower pulse
rates, compared to patients receiving the same ß2-agonist via wet
nebulisation. No outcomes were worse with the spacer in either
adults or children, even in those adults with more severe asthma
at presentation. All the studies reviewed excluded patients with
life-threatening asthma (for example those patients considered for
ventilation), and the results of the review should not be extrap-
olated to this group. Successful response to ß2-agonists does not
diminish the necessity to consider oral steroids in acute attacks
of asthma. A previous meta-analysis demonstrated that steroids
clearly reduce relapses when given to patients following discharge,
and reduce hospitalisation when used early in the course of emer-
gency treatment (Rowe 2007).
In clinical practice the dose of ß2-agonist delivered to the air-
ways varies depending on the type of nebuliser or spacer used
and the characteristics of the individual patient’s airways at that
time (Lipworth 1997). Uncertainty over the dose of ß2-agonists
required through any delivery method was overcome in many of
the studies (475 adults and 632 children) by repeating treatments
at short intervals. For example, one respule (via nebuliser) or four
to six puffs (via spacer) every 10 to 30 minutes until the patient
responded to treatment (Batra 1997; Chong-Neto 2005; Chou
1995; Colacone 1993; Duarte 2002; Idris 1993; Leversha 2000;
Ploin 2000; Rao 2002; Rodrigo 1993; Rodrigo 1998; Valencia
1999; Vivek 2003) were considered equivalent. This approach re-
duced confounding by different dosages of drug delivered.
In adults, no additional benefit was found using six puffs of Salbu-
tamol (100 mcg each) given at 10 minute intervals through a
Volumatic Spacer, when compared with four puffs at 10 minute
intervals (Rodrigo 1996). A comparison in children between doses
of 0.5 mg/kg and 1.5 mg/kg given at 20 minute intervals via neb-
uliser showed significantly greater improvement in lung function
at the higher dose (Schuh 1989).
The studies included in this reviewused dosage ratios varying from
1:1 to 1:13 (lower dose in the spacer). One of the included studies
plotted a log dose-response curve (Colacone 1993); the equivalent
dose ratio found in this study was 1:6 with the lower dose in the
spacer.
Experimental evidence suggests that the ß2 agonist should be actu-
ated into the spacer in individual puffs that can be inhaled by tidal
breathing or single breaths (Newman 1984; Gleeson 1988). Some
of the early studies mentioned difficulty with the valve movement
with some spacers; however, this did not appear to be a problem
in more recent studies. Some children may co-operate more with
either spacer or nebuliser, so this may be an important factor in
the choice of delivery method. Two studies compared different
types of spacer; Chong-Neto 2005 studied 10 children with ae-
rochamber and 10 with a home-made spacer constructed from
a 500 ml mineral water bottle. The study failed to identify dif-
ferences between the types of spacer, yet did demonstrate signifi-
cantly lower pulse rateswith theAerochamber thanwith the home-
made spacer. Williams 1996 included 20 children treated with an
Aerochamber and 22 children treated with an ACE spacer (both
around 150 ml) and found no significant differences between the
groups in respiratory rate and lung function.
Overall comparisons between types of spacer is confounded by all
the other differences between the designs of each trial. In view
of the discontinuation of Volumatic spacers in the UK in 2005,
additional details to allow identification of type of spacer used
have been added in Table 1. This indicates that the findings of
this review for the primary outcome of hospital admission are
unchanged in children when trials using Volumatic spacers are
excluded, but the confidence intervals widen for adults as less data
contributes to the outcome. No significant subgroup differences
were found for any outcome between the trials using Volumatic
or other spacers.
Cost considerations may dictate which delivery system is used in
different settings. In many parts of the world nebulisation is not
available in peripheral hospitals and clinics for economic reasons
(Rao 2002). Several recent studies have now included a calculation
of costs of drug treatment (Burrows 2004; Chong-Neto 2005;
Dewar 1999; Duarte 2002) and found a cost advantage for spacer
delivery.
Total costs in a hospital setting are more complex to calculate;
however, when patients return to the community the cost of a
home nebuliser and respules is considerably more than an MDI
and spacer (and the nebuliser requires regular maintenance). A
recent before-after ED study (Newman 2002) assessed the conse-
quences of changing the acute asthma treatment algorithm from
nebulised to MDI/spacer albuterol (salbutamol). Admission rates
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did not rise following the change in delivery method and duration
of stay in the ED fell significantly from 175 minutes to 164 min-
utes. There were also reductions in charges that did not reach sig-
nificance. Lower relapse rates following the change toMDI/spacer
delivery were confounded by other changes, such as an asthma bag
containing a spacer, peak-flow meter, instructional handout and
canister of inhaled corticosteroid given to the patients at discharge.
This makes data on relapse rates difficult to interpret, although
significant reductions were seen following the combined interven-
tions. As expected, the total dose of albuterol given to patients was
lower with MDI/spacer delivery.
IMPLEMENTATION OF CHANGE IN
PRACTICE
Implementing research findings is not an easy process, and Powell
2001 found that successfully changing hospital practice from neb-
ulisers to spacers required a structured strategy to overcome the
“nebuliser culture” both in hospital medical and nursing staff, as
well as parents and families of children with asthma. Osmond
2007 carried out a survey of the use of nebulisers and spacers in
Canadian paediatric emergency departments, and found that 21%
of emergency physicians used MDI and spacer; the largest per-
ceived barriers amongst non-users included safety and costs, and
the lack of a physician champion for change.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
(1) For adults seen and assessed for acute asthma, this review found
no significant differences between the two deliverymethods. Con-
sequently, the choice of delivery method should reflect patient
preference, practice situations and formal economic evaluation.
(2) In children, no outcomes were significantly worse with the
spacers, and the available evidence suggests that in most cases
spacers could be substituted for nebulisers to deliver ß2-agonists
in acute asthma. Moreover, other observed benefits (time spent in
emergency department, oxygenation and side effects) may favour
the groups treated with metered-dose inhaler and spacer.
(3) The experimental method adopted in many of the studies was
to give repeated treatments at short intervals (e.g. one respule via a
nebuliser or four actuations of a metered-dose inhaler via a spacer
every 10 to 15 minutes). The number of treatments required was
adjusted to the individual patients response, overcoming the un-
certainty of dosage delivery from different devices. This method
is therefore recommended for practice until further evidence be-
comes available.
(4) The studies excluded patients with life-threatening asthma;
therefore, the results of this meta-analysis should not be extrapo-
lated to this patient population.
Implications for research
(1) Further studies are required to confirm whether these findings,
largely from hospital emergency departments, can be replicated in
the community setting.
(2) Further studies in children and adults with more severe asthma
are required to confirm whether spacers are as efficacious as neb-
ulisers in this group.
(3) In order to avoid confounding due to differences in the dose
of drug delivered to the airways, future studies should use multi-
ple treatments at short intervals titrated against individual patient
response.
(4) Implementation of change to overcome the “nebuliser culture”
needs further work.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ba 1989
Methods Randomisation: no details.
Blinding: double blinded, double dummy.
Excluded:none.
Withdrawals: none.
Baseline characteristics: Comparable but the Chamber group had significantly lower FEV-1 at
baseline (P < 0.02).
Intention to treat analysis: not used.
Jadad score: 4
Participants Setting: Hospital inpatients, Canada.
27 children aged 7 to 18 years old (average age 11.9).
Inclusion/exclusion criteria: Salbutamol nebulisers and i. v. aminophylline given on admission. 3
hours post if FVC and FEV-1 were still < 65% predicted value then included, if above excluded
Interventions Beta2-agonist: Salbutamol
Spacer: Nebuhaler 750 ml pear shaped.
Nebuliser: Hudson, up draft 11 nebu-mist. Driven by continuous flow oxygen output 6L/min.
Chamber group: 2mls 0.9% saline (placebo) via nebuliser, immediately followed by continuous tidal
breathing of 2 puffs salbutamol every 10 seconds (total 12 puffs= 1.2mg) with MDI + Nebuhaler.
Nebuliser group: 1 ml (5mg) salbutamol added to 1 ml of 0.9% saline, immediately followed by
tidal breathing with a placebo via MDI + Nebuhaler.
Dose ratio 1:4
Co-interventions: All children had continuous i. v. aminophylline
Outcomes FEV-1 and FVC, pulse, blood pressure, respiratory rate, side effects. Assessed at -11 mins (before)
and 10, 30, 60, 90, 120, 180 (after) inhalation from the MDI and spacer. Maximum change in
FEV-1 and FVC from baseline
Notes Lower baseline FEV1 in the spacer group may have contributed to the larger improvement from
baseline in this group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
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Batra 1997
Methods Randomisation: computer generated random numbers.
Blinding: none.
Excluded: number not stated.
Withdrawals: none recorded.
Baseline characteristics: comparable.
Power analysis: 30 in each group designed to detect a 30% difference in response rate.
Jadad score: 2.
Participants Setting: India. Emergency department.
60 children aged 1 to 12 years (average age 4 years). PEF at presentation was under 40% predicted
in the 16 children able to undergo this evaluation.
Inclusion criteria: over two previous attacks of wheezing in response to allergens and exercise as
well as infection.
Exclusion criteria: TB, heart, liver, kidney or lung disease. Skeletal disorders
Interventions Beta2-agonist: Salbutamol.
Spacer: Volumatic (M/s Cipla) 750 ml.
Dosage: 2 puffs (200 mcg) given every 5 to 10 minutes for 60 minutes.
Nebuliser: no details.
Dosage: 0.15 mg/kg in 2.5 ml saline given three times at 20 minute intervals.
Co-interventions: all given humidified oxygen and none were given steroids
Outcomes Further treatment (?admission), PEF in 16 children, blood gases, symptoms score
Notes This trial was included as the mean age of the children was over 2 years old. No response from
authors to requests for further details
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer generated random numbers
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
Burrows 2004




Baseline characteristics: details awaited
Intention to treat analysis: details awaited
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Burrows 2004 (Continued)
Participants Southampton General Hospital.
29 children aged 1-6 years admitted to hospital with moderate or severe asthma.
Inclusion criteria: moderate or severe asthma according to BTS criteria.
Exclusion criteria: details awaited




Outcomes Duration of admission to hospital, oxygen saturation, increase in heart rate, increase in respiratory
rate, drug costs
Notes No SD data provided in abstract.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
Allocation concealment? Unclear Infomation not available
Blinding?
Hospital admission
Unclear Information not available
Chong-Neto 2005
Methods Randomisation: the children drew a slip of paper numbered 1,2,3,4 out of a non-translucent jar.




Power calculation:carried out on the basis of a 15% difference in FEV1 between groups
Participants Critiba, Brazil. 24-hour emergency health unit.
40 children aged 6 to 18 years old. 30 of these were included in this review (10 in each arm as
detailed below).
Inclusion criteria: Acute asthma attacks. Children were able to use the devices and carry out lung
function testing.
Exclusion criteria: History of cardiac and pulmonary diseases other than asthma, clinical score <
3, forced expiratory flow in the first second (FEV1) less than 20% and greater than 80% of the
predicted value. Smokers (> 10 packs of cigarettes/year), and children treated with short-acting and
long-acting beta-2 agonists in the last 24 hours, corticosteroids on the last seven days, and also
those receiving xanthines, were also excluded
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Chong-Neto 2005 (Continued)
Interventions Beta2-agonist: Salbutamol (Albuterol).
Spacer A: Aerochamber, 4 x 100 mcg separate actuations of salbutamol given at 30 second intervals,
inhaled using single deep breath per actuation. This was given three times at 20 minute intervals.
Home made Spacer: 500 ml plastic water bottle, 4 x 100 mcg separate actuations of salbutamol
given at 30 second intervals, inhaled using single deep breath per actuation. This was given three
times at 20 minute intervals.
Nebuliser: Pari Jet, 0.15 mg/kg salbutamol given every 20 minutes in 3 ml saline driven by Proned
ultra compressor (air driven).
Dosage ratio: Spacer/Nebuliser = 1/12.5.
Co-interventions: not specified.
(The further 10 children treated with dry powder inhaler were not included in this review)
Outcomes FEV1, admission to hospital, change in symptom score, increase in heart rate, tremor, nausea,
vomiting, hypokalaemia. Full data provided by authors
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; drawing of lots used
but unclear how numbered lots were drawn up
Allocation concealment? No Children randomised themselves by drawing lots
Blinding?
Hospital admission
Yes Double dummy design
Chou 1995





Intention to treat analysis: not required.
Jadad score: 3.
Participants New York. Urban paediatric emergency department.
152 children aged 2 years or older.
Mean PEF at presentation 56% and 53% in the treatment and control group.
Inclusion criteria: current wheeze and history of at least 2 episodes of wheezing.
Exclusion criteria: no patients were excluded from the study, but exclusion criteria included chronic
illness, presenting oxygen saturation less than 90% or symptom score >12
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Chou 1995 (Continued)
Interventions Beta2-agonist: Salbutamol (Albuterol).
Spacer: Aerochamber, 3x90mcg actuations of salbutamol given every 20 minutes, inhaled using
five normal breaths per actuation. (Mean 2.3 treatments given).
Nebuliser: Acorn II, 0.15 mg/kg salbutamol given every 20 minutes in 3 ml saline driven by oxygen
at 6 L per minute (Mean 2.5 treatments given).
Co-interventions: oxygen was given to all patients with an oxygen saturation of less than 94%while
breathing room air. Administration of steroids and other medication was at the discretion of the
treating physician
Outcomes Admission to hospital, duration in emergency department, change in symptom score, final Peak
Flow (in children old enough to perform test), oxygen saturation, increase in heart rate, adminis-
tration of steroids
Notes Standard deviation of results and details of randomisation obtained from author; SD of change in
lung function estimated
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table
Allocation concealment? Yes Sealed opaque envelopes
Blinding?
Hospital admission
No Open label study
Coker 1995





Intention to treat analysis: Not used.
Jadad Score: 1.
Participants Setting: Hospital inpatients, Turkey.
36 children, 12 in each group; 2 groups considered.
Mean age 10.33 (SD 1.15) (chamber).
11.75 (SD 1.60) (nebuliser.)
Inclusion Criteria: Children over 9 years, admitted with acute asthma crisis.
Exclusion criteria: if received any medicine in the last 8 hours
Interventions Beta2-agonist: Salbutamol Spacer: 750 ml Volumatic spacer using tidal breathing. 200 mcg (given
twice with interval of 2 mins in between).
Nebuliser: Pari-inhaler boy (ultrasonic) nebuliser driven by compressed air. 0.05-0.1mg/kg (max
dose of 2.5mg) nebules.
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Coker 1995 (Continued)
Co-interventions: none.
Outcomes Respiratory score (nasal flaring, cyanosis, retractions, wheezing), PEFR, respiratory rate, heart rate,
blood pressure. All measured at 5, 15, 30, 240, and 360 ( 6 hours) minutes after treatment
Notes Confirmation of doses, gained from author as well as, method of randomisation (alternation),
withdrawals and dropouts and co-interventions.
3rd arm of this trial using MDI only was disregarded.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternate allocation
Allocation concealment? No Allocation by alternation at high risk of bias in
terms of concealment of allocation
Blinding?
Hospital admission
No Not described as blinded
Colacone 1993
Methods Randomisation: no details but double blind.
Blinding: double blind.
Excluded: number not stated.
Withdrawals: five.
Baseline characteristics: comparable.
Intention to treat: not used.
Power calculation: performed, estimated 80%.
Jadad score: 5.
Participants Setting: Canada. Hospital emergency department.
80 adults mean age 41(SD18) and 43(SD19) years.
Mean FEV1(% predicted) at presentation: Spacer 55%(SD15), nebuliser 54%(SD18).
Inclusion criteria: acute asthma, FEV1<70% predicted, over 18 years old, able to perform spirom-
etry.
Exclusion criteria: pregnancy, complicating medical illness, already given nebulised or parenteral
beta-agonist in emergency department
Interventions Beta2-agonist: Salbutamol (Albuterol).
Spacer: Aerochamber.
Dosage: 4x100mcg puffs individually and inhaled by one slow inhalation at one minute intervals.
Treatment given every 30 minutes until maximum bronchodilation achieved.
Nebuliser: Disposable Updraft nebuliser.
Dosage: 2.5mg in 2ml saline driven by oxygen at 5 to 8 L/min. Repeated every 30 mins as above.
Dosage ratio: Spacer/Nebuliser = 1/6.
Co-interventions: steroids and aminophylline (stratified treatment arms)
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Colacone 1993 (Continued)
Outcomes Symptom score, FEV1, heart rate, respiratory rate, presence of tremor
Notes Cumulative dose response curve showed a relative potency of 1:6 in favour of spacer. One patient
was withdrawn from the spacer group due to clinical deterioration; included in review result as a
hospital admission on intention to treat basis. Estimated SD for respiratory rate and pulse rate
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Not reported
Allocation concealment? Unclear Not reported
Blinding?
Hospital admission
Yes Described as blinded
Dewar 1999
Methods Randomisation: sequential pre sealed envelopes.
Blinding: none.
Excluded:11 (2 immediately due to needing i. v. therapy, and 9 re-admitted during trial and not
re-studied.)
Withdrawals: 5 needed i. v. therapy post randomisation (3 chamber group, 2 nebuliser group).
8% did not complete follow up post discharge, but did complete trial in hospital.
Baseline characteristics: comparable.
Intention to treat: not used.
Sample size: estimated from asthma admissions data from previous 2 years.
Jadad score: 3.
Participants Setting: Hospital inpatients, UK. 62 children aged 3 or above: mean age 6.9yr (chamber) 8yr
(nebuliser).
Inclusion criteria: over 3 years, admitted with acute asthma.
Exclusion criteria: Children unable to use chamber mouthpiece effectively. Those requiring i. v.
treatment. Those readmitted during 5 month study period
Interventions Beta2-Agonist: Salbutamol.
Spacer: Large volume spacer (Volumatic).
Dosage: 100 mcg ,up to 10 puffs one hourly. Children and parents in the spacer group were
instructed and supervised on the optimal use of the delivery device. They were also provided with
a written treatment plan for managing acute asthma.
Nebuliser: jet nebuliser driven by oxygen 6-8 l/min.
Dosage: 5mg salbutamol up to 1 hourly.
Co-interventions: All children received oral prednisolone at 2 mg/kg (max. dose 60 mg) on admis-
sion and repeated on subsequent mornings for 3 to 5 doses according to recovery.
Oxygen was administered by face mask or nasal prongs in children who after bronchodilator
treatment had Ox. sats of < 93%
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Dewar 1999 (Continued)
Outcomes Hospital length of stay, cost, asthma morbidity 2 weeks after discharge, frequency of re admissions
during the study period and following 12 months
Notes All families given same discharge advice re: management of acute attacks, but seems only chamber
group received a written treatment plan. No response from author to confirm this.
Patients lost to follow up ignored: this can lead to bias.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; no other details avail-
able
Allocation concealment? Yes Sequential pre sealed envelopes
Blinding?
Hospital admission
No Open label study
Duarte 2002
Methods Randomisation: method not stated.
Blinding: assessors blinded.
Excluded: no details of how many patients were excluded.
Withdrawals: none.
Baseline characteristics: no significant differences.
Intention to treat analysis: not described.
Power calculation based on 15L/min difference in PEF.
Jadad score: 2.
Participants Setting: Brazil. Emergency Room.
196 children aged 4 to 15 years.
Mean PEF at presentation: Spacer 174 L/min, Nebuliser 173 L/min.
Inclusion criteria: two or more previous acute exacerbations, mild to moderate current attack (PEF
50% to 79% of predicted).
Exclusion criteria: severe acute asthma (PEF under 50% predicted), patients unable to perform
PEF, or use delivery devices, patients who had used controller or rescue medication in the past 2
weeks, and patients with complications (pneumothorax, pneumonia)
Interventions Beta2-agonist: Salbutamol.
Spacer: 500 ml plastic mineral water bottle coated with detergent
Dosage: Five separate 100 mcg actuations inhaled by tidal breathing for 20 seconds.
Nebuliser: Nevoni (Sao Paulo, Brazil). Driving gas oxygen at 6L/min
Dosage: 0.15 mg/kg salbutamol given up to maximum of 5mg
Each group had repeated Traitement up to 3 doses.
Dosage Ratio: 1 to 4 -10 (Spacer to Nebuliser)
Co-interventions: Not specified.
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Duarte 2002 (Continued)
Outcomes PEF, Pulse Oximetry, Heart Rate, Respiratory Rate, Clinical Score, Duration in Emergency Room
Notes Patients were discharged from the study when the PEF rose to 80% predicted or higher.
SD given for absolute values imputed for changes in Heart rate and Respiratory rate. PEF data not
shown as % predicted so not included
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label, only assessors were blinded
Freelander 1984




Baseline characteristics: comparable, but mean age 9.1 and 6.1 in treatment and control groups.
Intention to treat analysis: none.
Jadad score: 1.
Participants Setting: Australia. Accident and Emergency department.
28 children aged 3 to 13 years.
Mean PEF(% predicted) at presentation: Spacer 55%, Nebuliser 65%.
Inclusion criteria: no details.
Exclusion criteria: beta-agonist in previous 2 hours.
Interventions Beta2-agonist: Terbutaline.
Spacer: Nebuhaler. Dosage: 5 puffs (1.25 mg) under 20 kg, 10 puffs (2.5mg) over 20 kg. Details
of inhalation technique not given. (single treatment).
Nebuliser: Hudson driven by air at 6L/minute. Dosage: 2.5mg in 2ml saline under 20 kg, 5mg in
2ml saline over 20 kg. (single treatment).
Dosage Ratio: Spacer/Nebuliser = 1/2.
Co-interventions: no details.
Outcomes Admission to hospital, change in symptom score, change in Peak Flow (in children old enough to
perform test)
Notes Some children had difficulty triggering the Nebuhaler valve. Estimated SD for Peak Flow
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Freelander 1984 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
Hussein 2002




Baseline characteristics: not stated
Participants Setting: Alexandria, Egypt. Outpatient department study of children presenting with acute asthma
of moderate severity.
60 children aged 2 to 12 years.
Inclusion criteria: no details.
Exclusion criteria: no details.
Interventions Beta2-agonist: Salbutamol.
Spacer: ’Large volume’, up to 10 puffs of salbutamol given as single dose.
Nebuliser: No details of nebuliser type, 0.15mg/kg salbutamol given up to maximum of 5mg.
Driving gas not specified.
Co-interventions: Not specified.
Outcomes Admission to hospital, change in symptom score, pulmonary function, oxygen saturation, increase
in heart rate. 4 admissions in nebuliser group and 3 in holding chamber group. Symptoms, oxygen




Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
Allocation concealment? Unclear Information not available
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No No blinding recorded
Idris 1993
Methods Randomisation: double blind, no other details.
Blinding: double blind, double dummy.
Excluded: number not stated.
Withdrawals: none.
Baseline characteristics: comparable.
Intention to treat: not applicable.
Power calculation: performed, predicted 90% power to detect 12% difference in lung function.
Jadad score:5.
Participants Setting: USA. Hospital emergency rooms.
35 patients aged 10 to 45 years, mean age 23 (spacer) and 25(nebuliser).
Mean PEF(% predicted) at presentation: spacer 34(SD14), nebuliser 37(17).
Inclusion criteria: acute asthma.
Exclusion criteria: angina, respiratory failure, COPD, smoking for 10 pack years or more, unable
to perform spirometry
Interventions Beta2-agonist: Salbutamol (Albuterol).
Spacer: InspirEase.
Dosage: 4x90mcg puffs one puff every minute, inhaled by one slow inhalation. Treatment repeated
every 30 minutes until FEV1 was 80% predicted or patient asymptomatic or 6 treatments given.
Nebuliser: T Up-Draft II Nebu-U-Mist.
Dosage: 2.5mg in 2ml saline, driven by oxygen at 5 L/min. Treatment repeated every 30 minutes
until FEV1 was 80% predicted or patient asymptomatic or 6 treatments given.
Dosage ratio: Spacer/Nebuliser = 1/7. Mean dose to max response with spacer 1.11(SD 0.64)mg,
nebuliser 7.63(SD 3.9)mg.
Co-interventions: parenteral steroids usually given within one hour of discharge
Outcomes Further treatment (?admission), duration in emergency department, Peak Flow, FEV1,FVC, heart
rate, respiratory rate, administration of steroids
Notes Results include % maximum response (see footnotes). Separate analysis for patients with FEV1 <
30% predicted
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available
Allocation concealment? Unclear Information not available
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Methods Randomisation: Just described as randomised
Blinding: none.
Excluded: three out of 153
Withdrawals: none
Baseline characteristics: significantly higher PEF at baseline in spacer group
Participants Setting: Emergency Room of the National Institute of Child Health in Karachi fromOctober 2000
to March 2001
150 children (aged 6 months to 15 years). 76% were classified as having as severe asthma attack
(24% mild or moderate)
Inclusion criteria: acute asthma
Exclusion criteria: children requiring intensive care management, PEFR values under 20% or over
70% predicted, oxygen saturation under 90% in room air, or receiving daily systemic corticosteroids
for more than two weeks before being seen in the emergency room
Interventions Beta2-agonist: Salbutamol (Albuterol)
Spacer: Babyhaler for younger children and spacer with mouthpiece for older children.
Dosage: 2x100 mcg repeated three times at 20 minute intervals
Nebuliser: Type 2 Fleam Nuova S.P.A., Bresia, Italy.
Dosage: 0.3 mg/kg with 2ml Normal Saline repeated three times at 20 minute intervals
Dosage ratio: unknown.
Co-interventions: none reported.
Outcomes Admission to hospital. Pulse, Respiratory Rate, BP, Dyspnoea, Cyanosis, wheeze, PEFR, clinical
score, measured at 10 mins, 20 mins and 2 hours after completion of treatment
Notes No details are given for mean age in each group or how many children were able to perform PEFR.
Trial included as mean age is almost certainly over 2 years old
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details
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Kerem 1993
Methods Randomisation: assigned by research pharmacist.




Intention to treat analysis: not stated.
Jadad score:4
Participants Setting: Canada. Emergency Department.
33 children aged 6 to 14 years old.
Mean FEV1(% predicted) at presentation: Spacer 40%, Nebuliser 40%
Inclusion criteria: not stated.
Exclusion criteria: critically ill, FEV1< 20% or > 70%, oxygen saturation in air < 92%, systemic
steroids given for more than 2 weeks
Interventions Beta2-agonist: Salbutamol (Albuterol)
Spacer: VentAHaler.
Dosage: 6x100mcg (< 25 kg), 8 x 100 mcg (25 to 35 kg), 10 x 100 mcg (> 35 kg). Total dose
discharged into spacer followed by one minute tidal breathing, Single treatment.
Nebuliser: Whisper Jet, driven by oxygen at 6 to 10 L/min.
Dosage: 0.15 mg/kg to maximum 5mg given in 3 mls saline. Single Treatment.
Dosage ratio: Spacer/Nebuliser = 1/5.
Co-interventions: none.
Outcomes Admission to hospital, symptom score, FEV1, oxygen saturation, heart rate, respiratory rate
Notes Admission to hospital, symptom score, FEV1, oxygen saturation, heart rate, respiratory rate
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; no other information
available
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Leversha 2000
Methods Randomisation: pharmacy generated and blinded treatment packets supplied.
Blinding: double-blind, double dummy.
Excluded: number not stated.
Withdrawals: 1 from each group refused both treatments and was admitted. 1 from nebulizer
group refused the nebulizer but was treated with spacer and discharged. (All 3 were included in the
analysis).
Baseline characteristics: comparable for asthma severity.
Intention to treat: performed.
Power calculation: powered to detect a difference of 1.25 in clinical score between groups.
Jadad score: 5.
Participants Setting: New Zealand. Emergency department in children’s hospital. 60 children aged 1 to 4 years;
mean age 36 months (spacer) and 32 months. (nebuliser). 66% had received oral steroids in the
previous 24 hours in each group.
Inclusion criteria: Known history of asthma with a clinical score of greater than 3, presenting to
ED with acute asthma.
Exclusion criteria: bronchodilator given in the hour before presentation or requiring immediate
admission to intensive care unit. Also co-existing medical condition (such as pneumonia)
Interventions Beta2-agonist: Albuterol (Salbutamol).
Spacer: Aerochamber.
Dosage: 6x100mcg puffs inhaled separately by tidal breathing. Repeated every 20 minutes for a
maximum of 6 treatments.
Nebuliser: Marquest bowl with Hudson face mask.
Dosage: 2.5mg every 20 mins for a maximum of 6 treatments, driven by wall oxygen.
Double dummy methodology so placebo given by the other route to all children.
Co-interventions: supplemental oxygen if SaO2 less than 92% and oral prednisone unless child
had received oral steroids in past 24 hours.
Dosage ratio: Spacer/Nebuliser = 1/4
Outcomes Admission to hospital. Pulse, Respiratory Rate, SaO2, clinical score, tremor and hyperactivity
measured 20 mins after each treatment and 60 mins after final treatment
Notes Data in the paper is only provided for the results 20 mins after the first treatment.
One of the tables of data in the paper was inconsistent and has since been corrected. The data used
in the review for heart rate and respiratory rate has been provided by Dr Leversha
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; no other information
available
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Lin 1995
Methods Randomisation: Alternate weeks.
Blinding: none.
Excluded: number not stated.
Withdrawals: 4 from spacer group, 2 from nebuliser group.
Baseline characteristics: comparable.
Intention to treat: not performed.
Power calculation: not stated.
Jadad score:1.
Participants Setting: Taiwan. Hospital emergency department and paediatric allergy clinic.
111 children aged 5 to 16 years.
Mean PEF(% predicted) at presentation: spacer 57(SD20)%, nebuliser 60 (SD21)%.
Inclusion criteria: acute asthma or acute exacerbation of chronic asthma.
Exclusion criteria: inhaled beta-agonist in previous 6 hours, unable to perform spirometry, pneu-
monia, congestive heart failure, foreign body aspiration, bronchopulmonary dysplasia
Interventions Beta2-agonist: Terbutaline.
Spacer: Aerochamber.
Dosage: 3 x 0.25 mg puffs, each inhaled by three deep breaths. Single treatment.
Nebuliser: Pulmo-Aide.
Dosage: 2.5mg in 2ml saline, driven by air at 8 L/min. Single treatment.
Dosage ratio: Spacer/Nebuliser = 1/3.5.
Co-interventions: not stated.
Outcomes Measured at 15 minutes after the start of treatment: symptom score, Peak, FEV1, FVC, oxygen
saturation, heart rate
Notes Mean fall in SaO2 at 15 minutes was 0.47(SD 1.93)% in the nebuliser group, compared to a mean
rise of 0.58(SD 1.72)% in spacer group. Estimated SD for Peak Flow and pulse rate
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternate weeks




No Open label study
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Maldano 1997
Methods Randomisation: No data.
Blinding: None.
Excluded: No data.
Withdrawals: All patients completed the study.
Baseline characteristics:similar.
Power calculation: “approximately 90%”.
Jadad score: 2.
Participants Setting: ER Hospital Infantil de Mexico Fredrico Gomez.
42 children aged 6 to 15; baseline FEV1 69% (spacer) and 77% (nebuliser).
Inclusion criteria: FEV1 of 60% to 80% of predicted value.




Dosage: 2x100mcg twice 20 mins apart.
Nebuliser: Hudson driven by oxygen, dose 0.15 mg/kg up to maximum of 5mg made up to 5 ml
with saline. Given twice 20 minutes apart.
Dose ratio up to 1:25.
Outcomes FEV1 at 1,2,3,4,5,6 hours.
Pulse rate rise.
Symptoms using Silverman-Anderson scale.
Notes No standard deviations reported. After 3 hours following treatment the spacer group FEV1 had
fallen significantly more than the nebuliser group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
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Morley 1988
Methods Randomisation: Alternate allocation.
Blinding: None (discharge was at the discretion of the attending physician who had no involvement
in data acquisition- however this information could be requested if needed!)
Excluded: None.
Withdrawals: none withdrew however 2 patients data was excluded from daily rates of spirometric
improvement as spirometric analysis required was not completed.
Baseline Characteristics: Comparable
Intention to treat: not used
Jadad score: 1
Participants Setting: Hospital inpatients, New Jersey.
28 adults, admitted with acute status asthmaticus. Mean age of 34.8 (15.9) chamber group, 31.3
(19.0) nebuliser group.
Inclusion criteria: acute status asthmaticus, admitted after failing multiple trials of either subcuta-
neous or nebulised beta-agonists.
Exclusion criteria: A smoking history of > 5 packs a year of cigarettes, emphysema, respiratory
acidosis on admission, or pregnant. Unstable coronary insufficiency, recent myocardial infarction,
or cardiac arrhythmia were also excluded
Interventions Beta2-agonist: Albuterol (Salbutamol).
Spacer: InspirEase, Key Pharmaceutical.
Dosage: 3 inhalations (90 micrograms /inhalation) each separated by 5-min intervals. Received
every 4 hours.
Nebuliser: Acorn 2 nebulizer (Marquest Medical Products Inc, Englewood, CO).
Dosage: 0.5 ml (2.5mg) albuterol and 2.0 mls normal saline solution nebulised over 15 min period.
Received every 6 hours while awake.
Additional therapies: All patients received standard IV dosages of aminophylline. IV methylpred-
nisolone was administered as recommended by Haskell et al.
No oral beta-agonists were used.
(Group 3 received 15 mg nebulised metaproterenol)
Outcomes Spirometric improvement (FEV-1 and FVC) 15, 30, 60, 120, 180, 240 mins following the 1st
beta-agonist treatment (best of 2 recorded), duration of hospital stay (discharge criteria: free of
wheezing on auscultation and no exertional dyspnoea when walking on ground level), daily rates of
spirometric improvement during course of hospitalization (performed once in morning and once
in afternoon at similar times every day-just prior to treatment). Following 3rd day spirometry was
not performed again until discharge (calculations were based on assumption of discharge day at
day 6)
Notes Trial begins from initial beta-agonist dose given once admitted (at least 4 hours after last dose given
in A+E.) No data of how much given before trial commenced.
3rd arm of this trial ignored as different beta-agonist used
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternate allocation
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Morley 1988 (Continued)




No Open label study
Morrone 1990





Intention to treat: not applicable.
Jadad score: 2.
Participants Setting: Brazil. Mobile clinic.
44 adults, 36 female, 8 male.
Mean PEF(% predicted) at presentation: 180 L/min (% predicted not stated).
Inclusion criteria: PEF 120 to 200 L/min at presentation.
Exclusion criteria: not stated.
Interventions Beta2-agonist: Fenoterol.
Spacer: 500 ml (type not stated).
Dosage: 1 mg delivered as 200 mcg per minute inhaled by tidal breathing. Single treatment.
Nebuliser: type not stated.
Dosage: 2.5mg in 3 ml saline driven by oxygen at 6 L/min. Single treatment.
Dosage ratio: Spacer/Nebuliser = 1/2.5.
Co-interventions: none.
Outcomes Peak Flow. Actual readings changed to % predicted by assuming expected peak flow of 500 l/min
as original data has been lost
Notes Only the first part of this study compared spacer against nebuliser, the second part of the crossover
was not analysed due the high likelihood of contamination. Estimated SD for Peak Flow.
Data was measured from graph published in errata. (Rev Paul Med 1990;108:98)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? No Alternate allocation
Allocation concealment? No Investigators had foreknowledge of treatment
group assignment
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No Open label study
Parkin 1995
Methods Randomisation: No details.
Blinding: Single (nurse measuring outcomes only).
Excluded: none.
Withdrawals: 4 failures (stopping criteria not given).
Baseline characteristics: Clinical asthma score was 5.7 chamber, 4.8 nebuliser (P=0.02) therefore
an adjusted mean used.
Intention to treat analysis: performed.
Power analysis: 30 in each group designed to detect approximately 90% difference in asthma score.
Jadad score: 2.
Participants Setting: Hospital inpatients (after stabilisation in emergency department), Canada.
60 children aged 1-5 years old (2.9 years mean) Inclusion criteria: moderate acute asthma.
Exclusion criteria: not stated.
Interventions Beta2-agonist: Salbutamol and ipratropium bromide.
Spacer: Aerochamber 140 ml cylindrical with one way valve and mask.
Dosage: Salbutamol 400 mcg for those <12 kg, 500 mcg for 12-16 kg, 600 mcg 16 kg or over. All
had 40 mcg ipratropium bromide also.
Nebulizer: Driven by compressed air, using a face mask
Dosage: Salbutamol 0.15 mg/kg/dose (maximum 5 mg) + ipratropium bromide 125 micrograms,
suspended in 3 mls of 0.9% saline over 15 minutes.
Drug ratio: Assumed drug ratio of nebuliser : MDI and chamber as 1:4.
Co-interventions: All participants received systemic corticosteroids.(i. v. or oral)
Outcomes Primary outcome: 10 point clinical asthma score measuring:
respiratory rate, wheezing, indrawing, observed dyspnoea, and inspiratory to expiratory ratio (Mea-
sured up to 60 hrs).
Secondary measures:
time to discharge,
time to 4 hourly dosing interval,
total number of inhaled doses required, nurses assessed ease of administration and participants
tolerance on a Likert scale, parents reported symptoms at 7 and 14 days post discharge
Notes Single blinding may have been appropriate due to age of participants i.e. little placebo effect in 1
to 5 year olds.
Trial sponsored by Aerochamber and Metered dose inhaler companies.
Study included as mean age over 2 years.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
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Parkin 1995 (Continued)
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Single blind (assessor only)
Pendergast 1989
Methods Randomisation: method not stated.
Blinding: none.
Excluded: not stated.
Withdrawals: 4 from spacer group.
Baseline characteristics: compared.
Intention to treat: not done.
Power calculation: estimated 80%.
Jadad score: 2.
Participants Setting: Australia. Acute presentation at Children’s Hospital.
27 children aged 3 to 6.8 years.
Mean symptom score at presentation: 2.13(0.49) and 2.30(0.46) in spacer groups, 2.42(0.55) in
nebuliser group.
Inclusion criteria: not stated.
Exclusion criteria: not stated.
Interventions Beta2-agonist: Terbutaline.
Spacer: Nebuhaler.
Dosage: Low dose group = one puff (0.25 mg) per 5 kg.
High dose group = two puffs (0.5 mg) per 5 kg. Each dose (bursts of 3 or 4 puffs) inhaled with 2
breaths and then a minute of tidal breathing.
Nebuliser: Unicorn.
Dosage: 0.2 mg per kg weight in 2ml saline (max 5mg) driven by oxygen at 6L/min.
Dosage ratio: Spacer/Nebuliser = 4/1 or 2/1.
Co-interventions: none.
Outcomes Admission to hospital, symptom score.
Notes Withdrawals: 3 from spacer group due to inability to co-operate and 1 from spacer group due to
clinical deterioration.
Vague descriptions of outcome (“no difference” between number in each group needing a second
treatment or admission to hospital).
Lower dose spacer group showed a trend to deterioration on score between 30 and 60 minutes after
treatment which did not reach significance (P 0.05)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
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Pendergast 1989 (Continued)
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
Ploin 2000
Methods Randomisation: in blocks of 4.
Blinding: Double-blind, double dummy design.
Excluded: not stated.
Withdrawals: none.
Baseline characteristics: SaO2 was significantly lower in the Holding Chamber group.
Intention to treat analysis: yes.
Power analysis: yes.
Jadad score: 5.
Participants Setting: Paediatric emergency department of 2 teaching hospitals in Lyon (France).
64 children recruited aged 1 to 5 years; mean ages 24.8 months (chamber) and 25.5 months
(nebuliser). One child excluded from the analysis due to being randomised twice.
Inclusion criteria: Acute wheezing in children with at least 3 episodes of wheezing or 3 episodes
with a family history of atopy, eczema or asthma.
Exclusion criteria: SaO2 less than 90%, inhaled or systemic steroids within the past 24 hours, or
underlying chronic disease
Interventions Beta2-agonist: Albuterol (Salbutamol).
Spacer: Babyhaler.
Dosage: 50 mcg/kg (maximum of 10 puffs) each puff followed by 8 breaths over 1 to 2 minutes.
Treatment given at 20 minute intervals for 60 mins.
Nebuliser: Ultrasonic (ARP 70) used in room air.
Dosage: 150 mcg/kg diluted in 4 ml Saline over 8-9 minutes. Repeated at 20 minute intervals.
Dose ratio: 1:3 (Spacer:Nebuliser).
Duration 60 minutes and double dummy design.
Outcomes Change in Pulmonary Index, Hospital admission, ease of use, improvement in SaO2
Notes Clarification of inclusion criteria, and reasons for hospital admission provided by the author.
Study included as the mean age was over 2 years and care was taken to exclude children with viral
bronchiolitis
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Blocks of 4 computer generated
Allocation concealment? Unclear o information
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Methods Randomisation: no details.
Blinding: none.
Excluded: number not stated.
Withdrawals: none.
Baseline characteristics: comparable.
Intention to treat: not stated.
Power calculation: carried out but in the event the study was underpowered.
Jadad score: 2.
Participants Setting: Argentina, Emergency Department at Hospital Ferrer, Buenos Aires.
27 adults with asthma according to the ATS criteria.
Inclusion criteria: severe asthma attack defined as FEV1 < 1 litre or < 30% predicted.
Exclusion criteria: smokers, pregnant, pneumothorax, pneumonia or in extremis
Interventions Beta2-agonist: Albuterol (Salbutamol).
Spacer: Aerochamber.
Dosage: 400 mcg delivered as four separate actuations, each one inhaled by 3 deep breaths and
repeated at 60 second intervals. Repeated every 30 mins for 2 hours and then hourly until the sixth
hour.
Nebuliser: Puritan-Bennett Raindrop.
Dosage: 5mg given over 5 to 10 minutes and repeated as above.
Dose Ratio: 1:13 (Spacer:Nebuliser).
Co-interventions: all patients received 8 mg Dexamethasone IV and were given oxygen
Outcomes FEV1, hospital admission
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
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Rao 2002
Methods Randomisation: no details




Intention to treat: not stated.
Power calculation: not stated.
Participants Setting: Pakistan, Hospital emergency departments in 2 hospitals in Karachi.
50 adults aged 18 to 62, (mean age 40), with acute asthma exacerbation (moderate to severe
according to BTS guidelines). Initial mean PEF 27-30% predicted .
Inclusion criteria: acute asthma defined by signs, symptoms and peak flow readings.
Exclusion criteria: unable to perform spirometry, history of respiratory failure, COPD, IHD or
arrhythmias, smoking history of more than 10 pack years or pregnancy
Interventions Beta2-agonist: Salbutamol.
Spacer: Not specified.
Dosage: 4x100 mcg one puff every minute for 4 doses repeated at 30 minute intervals until patient
improved or FEV1 rose to 70% predicted or 3 doses had been administered.
Nebuliser: Not specified.
Dosage: 2.5mg in 2.5 ml saline driven by oxygen at 5 L to 6L per minute, given at 30 minute
intervals until patient improved or FEV1 rose to 70% predicted or 3 doses had been administered.
Dosage ratio: Spacer/Nebuliser 1/6.
Co-interventions: not specified.
Outcomes FEV1, PEF, FVC, and pulse rate at 30 and 60minutes. Hospital admission. After the first treatment
17 spacer patients and 13 nebuliser patients improved and did not require the second or third
treatments
Notes 16% of patients in each group were smokers, and none were taking inhaled therapy at presentation.
SD for change in FEV1 based on published absolute SD (conservative estimate)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
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Robertson 1998
Methods Randomisation: no details.
Blinding: Double-blind, double dummy design.
Excluded: not stated.
Withdrawals: 27 due to inadequate response.
Baseline characteristics: comparable.




Participants Setting: Australia, multi-centre in Emergency Departments.
155 children recruited aged 4 to 12 years, 147 evaluable.
Inclusion criteria:PEF under 70% predicted (aged over 7) or clinical score of > 4 out of 12.




Dosage: 600 mcg (under 25 kg) and 1200 mcg (over 25 kg) given in bursts of 3 puffs with 15
seconds of tidal breathing.
Nebuliser: AVA-NEB Hudson.
Dosage: 2.5mg (> 25 kg) or 5mg (> 25 kg) in 2.5 ml saline driven by oxygen at 8 to 10 L/min.
Dose ratio 1:4.2 (Spacer: Nebuliser).
Single dose study.
Outcomes Withdrawal to further treatment, PEF, pulse, Blood pressure, tremor and symptom score
Notes 15 withdrawals in spacer group and 12 in nebuliser group. Both groups showed 1% increase in
SaO2
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available




41Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rodrigo 1993
Methods Randomisation: random numbers.




Intention to treat: not stated.
Power calculation: not stated.
Jadad score: 4.
Participants Setting: Uruguay. Hospital emergency room.
97 adults aged 18 to 50.
Mean PEF(% predicted) at presentation: 32% in each group.
Inclusion criteria: “criteria of the American Thoracic Society”.




Dosage: 4 X 100 mcg every 10 minutes, each puff inhaled with two deep inhalations from the
spacer.
Nebuliser: Ava-Neb.
Dosage: 1.5 mg in 4 ml saline driven by oxygen at 8 L/min at 15 minute intervals.
Dosage ratio: Spacer/Nebuliser = 1/2, (mean total dose 5.61 mg/11.8 mg).
Co-interventions: oxygen by nasal prongs 4 L/min given to all participants. All participants received
oral steroids at discharge
Outcomes Admission to hospital, duration in emergency department, Peak Flow, FEV1, FVC, heart rate,
development of tremor
Notes Separate analysis was performed on those participants admitted and those with FEV1 < 0.9 L.
Estimated SD for final Peak Flow in holding chamber group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table
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Rodrigo 1998
Methods Randomisation: random numbers.
Blinding: double blind, double dummy.
Excluded: number unknown.
Withdrawals: no data, ?none.
Baseline characteristics: comparable.
Intention to treat: no data.
Power calculation: powered to detect a 36% difference (0.6 litres) in FEV1.
Jadad score: 4.
Participants Setting: Uruguay, Hospital emergency room in Montevideo.
22 adults aged 18 to 50 with acute asthma exacerbation (all met ATS criteria for asthma). Initial
mean PEF 30% predicted and SaO2 95%.
Inclusion criteria: PEF and FEV1 both below 50% predicted at presentation.
Exclusion criteria: other chronic disease or pregnancy.
Interventions Beta2-agonist: Salbutamol.
Spacer: Volumatic.
Dosage: 4x100 mcg every 10 minutes, (2.4 mg per hour)
Nebuliser: Hudson T Up-draft flow rate 8 L/min.
Dosage: 1.5 mg in 4 ml saline driven by compressed air at 8 L/min at 15 minute intervals.
Dosage ratio: Spacer/Nebuliser 1/2.3.
Co-interventions: oxygen was allowed in the protocol if SaO2 fell below 90% but was not required
in any participant. 500 mg of hydrocortisone was given to all patients with a poor response after 3
hours
Outcomes FEV1, PEF, QTc interval, SaO2 (arterial oxygen saturation) every 30 minutes. Potassium and
Salbutamol blood levels at start and 3 hours
Notes Neither group showed a deterioration in oxygen saturation and no oxygen was needed in this study.
Final plasma salbutamol was 10.1 (SD 1.6 ng/m) in spacer group and 14.4 (SD 2.3 ng. ml) in
nebuliser group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table
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Rodriguez 1999
Methods Randomisation: random number table used but allocation not concealed.
Blinding: outcomes evaluated by an observer blinded to the treatment allocated.
Excluded: number not stated.
Withdrawals: there were none.
Baseline characteristics: similar in the two groups.
Intention to treat: not required.
Power calculation: not stated.
Jadad score: 1.
Participants Setting: Colombia. Hospital emergency department (University Hospital of San Ignatio).
69 adults (56 women) mean age 39 years. Mean PEF at baseline 186 L/min, SD 78 L/min (spacer
group) and 179 L/min SD 89 L/min (nebuliser group).
Asthma severity: 26 mild asthma attack, 20 moderate and 23 severe.
Inclusion criteria: “acute exacerbation of asthma” defined clinically.
Exclusion criteria: no details.
Interventions Beta2-agonist: Salbutamol.
Spacer: Volumatic.
Dosage: 4x100mcg every 10 minutes for one hour (no details of inhalation method).
Nebuliser: type not stated.
Dosage: 2.5mg every 20 mins for one hour.
Dosage ratio: Spacer/Nebuliser 1/3.
Co-interventions: not stated.
Outcomes Admission to hospital. Heart rate, respiratory rate, PEF, every 20 mins and at 120 mins. Blood
gases at baseline and 120 mins
Notes Unpublished data supplied by authors. Standard deviations provided for each time period, and
imputed to the change measurements
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? No Allocation not concealed
Blinding?
Hospital admission
No Outcomes evaluated by an observer blinded to
the treatment allocated
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Salzman 1989
Methods Randomisation: random numbers.
Blinding: double blind, double dummy.
Excluded: number not stated.
Withdrawals: six patients, none for worsening clinical status.
Baseline characteristics: comparable, except baseline FEV1 lower in the spacer group.
Intention to treat: not done.
Power calculation: not stated.
Jadad score: 5.
Participants Setting: USA. Hospital emergency department.
44 adults. Spacer group mean age 32.5 yrs (SD 12.5), nebuliser group mean age 28 yrs (SD 10.3).
Mean FEV1(% predicted) at presentation: Spacer 26% (SD 12.1%), nebuliser 33% (SD 16%).
Inclusion criteria: acute asthma FEV1< 50% predicted.
Exclusion criteria: COPD, pneumothorax, depression, PaCO2 > 40, ventilation required
Interventions Beta2-agonist: Metaproterenol sulphate.
Spacer: Aerochamber.
Dosage: 3x0.65 mg puffs each 5 minutes apart. Single treatment. No details of breathing method.
Nebuliser: type not stated.
Dosage: 15 mg in 2ml saline over 10 minutes. Single treatment. Dosage ratio: Spacer/Nebuliser =
1/8.
Co-interventions: none.
Outcomes Admission to hospital, FEV1, FVC, heart rate, respiratory rate
Notes Rise in FEV1 (% predicted) calculated from data given in paper
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table





Methods Randomisation: Allocation by numbered envelopes
Blinding: none
Excluded: 106 of 185 children presenting during working hours were excluded
Withdrawals: none for the initial study, six families were lost to longer term follow-up
Baseline characteristics: comparable, except imbalance in respiratory rate
Participants Setting: Pediatric Emergency Department in France .
79 children aged 4 to 15 years (mean age 9 years). 40 patients allocated to nebuliser and 39 allocated
to spacer.
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Sannier 2007 (Continued)
Inclusion criteria:severe acute exacerbation of asthma (Bishop score >6 or SaO2 less than 92%). The
definition of severe asthma was understood as an acute attack developing over more than 24 hours
(or nocturnally), non-responsive to beta-agonist therapy (initiated prior to hospital presentation),
or occurring in spite of maintenance treatment with inhaled steroids (+/- beta-agonist), or recurring
within 1 month of oral steroid treatment and an attack occurring in a child with previous treatment
in intensive care for acute asthma.
Interventions Beta2-agonist: Salbutamol or Terbutaline
Spacer: Babyhaler/Volumatic or Nespacer/Nebuhaler (according to child’s home use).
Dosage: 6x100mcg salbutamol or 6x250mcg terbutaline every 20 minutes for six doses (each
inhalation was separated by 8 to 10 valve movements).
Nebuliser: Mininebuliser AIRVIE, Peters, Bobigny, France. Driven by oxygen at 6 L/min.
Dosage: 0.15mg/kg salbutamol in 4 ml saline every 20 mins for six doses (minimum 1.5 mg to
maximum 5 mg per dose).
Dosage ratio: Spacer/Nebuliser 1/3 to 1/5.
Co-interventions: all patients received oral steroids at the start of treatment
Outcomes Hospitalisation, Pulse Rate, Respiratory Rate, SaO2, PEF
Notes Baseline imbalance in Respiratory Rate noted, which may have contributed to the larger fall in the
nebuliser group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details





Methods Randomisation: double blind.
Blinding: double blind, double dummy.
Excluded: 26 out of 101 evaluated.
Withdrawals: not stated.
Baseline characteristics: comparable.
Intention to treat: not stated.
Power calculation: not stated.
Jadad score: 4.
Participants Setting: USA. Hospital emergency room.
53 adults with asthma 18 to 75 years old, 22 participants with COPD also in study but excluded
from this review.
Mean FEV1 at presentation: Spacer 1.2 L (SD 0.1), Nebuliser 1.1 L (SD 0.1)
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Turner 1988 (Continued)
Inclusion criteria: onset symptoms < 30 years or < 10 pack years smoking.
Exclusion criteria: pregnancy, suspected MI or CCF, intubation required
Interventions Beta2-agonist: Metaproterenol.
Spacer: Inspirease.
Dosage: 3 x 0.65 mg puffs at 2 minute intervals inhaled by 2 slow inhalations each. Total of three
treatments at 30 minute intervals.
Nebuliser: Acorn II.
Dosage: 15mg in 2ml saline given over 10minutes. Total of three treatments at 30minute intervals.
Dosage ratio: Spacer/Nebuliser = 1/8.
Co-interventions: oxygen and intravenous steroids given at the discretion of the emergency room
physician who was not involved in the study
Outcomes Admission to hospital, symptom score, FEV1, oxygen saturation, heart rate, respiratory rate, ad-
ministration of steroids
Notes Standard deviations calculated from raw data supplied by the author. Predicted Peak Flow estimated
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Described as randomised; other information not
available





Methods Randomisation: Random number table, no details of allocation concealment.
Blinding: none.
Excluded: number not stated.
Withdrawals: not stated.
Baseline characteristics: comparable.
Intention to treat: not stated.
Power calculation: not stated.
Jadad score:1.
Participants Setting: Casualty Department of Children’s hospital in Columbia. 70 Children with acute asthma
aged from 1 to 6 years old mean age 3.2 years (Spacer) and 3.6 years (Nebuliser). Mean Oxygen
saturation 92% (Spacer) and 91% (Nebuliser).
Inclusion criteria: acute asthma exacerbation.
Exclusion criteria: not stated.
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Valencia 1999 (Continued)
Interventions Beta2-agonist: Salbutamol.
Spacer: Type unspecified (500ml size).
Dosage: 2x100mcg given three times at 20 minute intervals.
Nebuliser: Breath Neb II.
Dosage: 0.15mg/kg diluted in 4 ml of Saline, given three times at 20 minute intervals.
Dosage ratio: not stated.
Co-interventions: not stated.
Outcomes Respiratory rate, oxygen saturation, patient rating, clinical response all after 60 minutes
Notes Paper states that two doses of 100 mg were given via Spacer but this has been assumed to be a
misprint for 100 mcg
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random number table
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
Vazquez 1992
Methods Randomisation: no details.
Blinding: none.
Excluded: number not stated.
Withdrawals: not stated.
Baseline characteristics: comparable.
Intention to treat: not stated.
Power calculation: not stated.
Jadad score: 1.
Participants Setting: Spain. Hospital Emergency Room.
18 children with asthma. Mean age 9.33 years (Spacer), 8.66 years (Nebuliser).
Mean FEV1 (% predicted): Spacer 41.3% (sd 16%), Nebuliser 39.6%(sd 19%) .
Inclusion criteria: FEV1 less than 65% predicted and no bets-agonist given in the previous 2 hours
Interventions Beta2-agonist: Salbutamol.
Spacer: Volumatic.
Dosage: 5 x 100 mcg together into spacer followed by 30 seconds of tidal breathing. Followed by
10 x 100 mcg every 20 minutes until stable or 1.5 mg/kg maximum dose.
Nebuliser: Type not stated.
Dosage: 500 mcg diluted in 3 ml driven by oxygen at 7 L/min
Dosage ratio: Spacer/Nebuliser = 1.3/1 Total average dose by spacer 3.2 mg(SD1mg) and by
nebuliser 2.5mg(SD 0.7 mg).
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Vazquez 1992 (Continued)
Co-interventions: not stated.
Outcomes Admission to hospital, Peak Flow, FEV1, FVC, oxygen saturation, heart rate
Notes Improvement in lung function expressed as % maximum predicted (see footnote).
No significant changes in blood gases in both groups.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
Allocation concealment? Unclear Informaion not available
Blinding?
Hospital admission
No Open label study
Vivek 2003
Methods Randomisation: using a table of random numbers. Concealment of allocation unclear.
Blinding: unblinded study
Excluded: number not stated.
Withdrawals: none
Baseline characteristics: “comparable”
Power calculation: not stated.
Participants Setting: South India. Emergency Room.
122 adults and children aged 10 to 50 years. 54 patients allocated to nebuliser and 68 allocated to
spacer.
Mean PEF at presentation: 200 - 250 L/min
Inclusion criteria:acute exacerbation of asthma (PEF 200 - 250 L/min).
Exclusion criteria: not stated.
Interventions Beta2-agonist: Terbutaline
Spacer: Astra Spacehaler (750 ml)
Dosage: 6 puffs of 0.25 mg. Treatment repeated at 5 and 30 minutes. Each puff inhaled separately.
Nebuliser: Aerofamily nebuliser
Dosage: 5mg (0.5 ml respirator solution + 1.5 ml normal saline). Treatment repeated at 5 and 30
minutes.
Dose ratio: 1:4 (Spacer:Nebuliser).
Duration 60 minutes.
Outcomes Endpoint: Terbutaline doses were administered until:
1. PEFR increased to 250 l/min or
2. Patient becomes asymptomatic
3. Three doses of terbutaline given
4. Side effects/Clinical deterioration occurred
49Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Review)




Item Authors’ judgement Description
Adequate sequence generation? Yes Random numbers table





Methods Randomisation: no details given.
Blinding: none.
Excluded: Children under six years old. Impending respiratory failure.
Withdrawals: none.
Baseline characteristics: comparable.
Intention to treat analysis: not required.
Jadad score: 2.
Participants Denver. Urban paediatric emergency department.
60 children aged 6 years or older.
Mean PEF at presentation 46% predicted.
Inclusion criteria: past history of asthma or current reversibility with albuterol.
Exclusion criteria: corticosteroid therapy in the past 7 days, chronic cardiopulmonary disease other
than asthma and severe presentation (depressedmental status, cyanosis impending respiratory failure
Interventions Beta2-agonist: Salbutamol (Albuterol).
Spacers: Aerochamber (20 patients) and ACE (22 patients), 4 x 90 mcg actuations of salbutamol
given separately every 30 minutes, inhaled using tidal breathing for one minute each. Three treat-
ments given at 30 minute intervals.
Nebuliser: PARI-JET II 2.5mg of Albuterol given every 30 minutes in 3 ml saline driven by
pressurised air at 6 L per minute. Three treatments given at 30 minute intervals.
Co-interventions: oxygen was given to all participants with an oxygen saturation of less than 92%
while breathing room air. All participants were given oral prednisolone at a dose of 2 mg/kg
(maximum 60 mg) within 30 minutes of enrolment
Outcomes Admission to hospital, change in % predicted Peak Flow, change in % predicted respiratory rate
Notes The results for the two spacers were pooled. Four participants required additional treatment in the
emergency department with one to three further treatments with nebulised albuterol before they
were discharged; these were 1 from the nebuliser group and 3 from the spacer groups
Risk of bias
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Williams 1996 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear Information not available
Allocation concealment? Unclear Information not available
Blinding?
Hospital admission
No Open label study
PEF- Peak Flow; FEV1- Forced expiratory volume in one second; %max predicted = (post treatment - basal)/(predicted - basal); puff -
actuation of metered-dose inhaler.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beasley 1985 Probably hospitalised patients and no response from authors to request for further information
Benton 1989 Not randomised.
Berenberg 1985 Mixed population of patients, not possible to separate data from asthmatics and no response from authors
Campbell 1995 No randomisation.
Deerojanawong 2005 Mean age of children was under 2 years
Fuglsang 1986 Cross-over design inappropriate for acute asthma.
Hodder 1988 No outcomes presented in this abstract in a form that could be used. No response from author
Jasper 1987 Mixed population of patients, not possible to separate data from asthmatics and no response from authors
Levitt 1995 Mixed population of COPD and asthma; no separate data given for asthmatic patients. No response from
author
Madsen 1982 No useable data and no response from authors.
Maguire 1991 Probably hospitalised patients, no response from authors to request for clarification
Mandelberg 1997 Mixed population of COPD and asthma; no separate data given for asthmatic patients. No response from
author
Mandelberg 2000 Infants and young children with a median age of 16 months.
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(Continued)
Morgan 1982 No standard deviation published in paper and no reply from authors. No useable data
Newman 2002 Non randomised (before and after study).
Rubilar 2000 Study in infants of 1 to 24 months.
Shaikh 2001 Not acute asthma.
Shim 1984 Not acute asthma.
Summer 1989 Different beta-2-agonists used.
Tarala 1980 No holding chamber used.
Vilarinho 2003 Not acute asthma. Children using bronchodilators or corticosteroids were excluded
Wildhaber 1999 Not acute asthma.
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D A T A A N D A N A L Y S E S
Comparison 1. Spacer (chamber) versus Nebuliser (Multiple treatment studies)




participants Statistical method Effect size
1 Hospital admission 16 1136 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.61, 1.12]
1.1 Adults 8 524 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.63, 1.49]
1.2 Children 8 612 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.47, 1.09]
2 Hospital admission or poor
response to treatment
18 1266 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.68, 1.18]
2.1 Adults 8 524 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.63, 1.49]
2.2 Children 10 742 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.60, 1.23]
3 Duration in emergency
department (hours).
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Adults 2 132 Mean Difference (IV, Fixed, 95% CI) 0.02 [-0.40, 0.44]
3.2 Children 3 396 Mean Difference (IV, Fixed, 95% CI) -0.53 [-0.62, -0.44]
4 Final rise in FEV1 (% predicted) 8 355 Mean Difference (IV, Fixed, 95% CI) 1.03 [-1.97, 4.04]
4.1 Adults 6 307 Mean Difference (IV, Fixed, 95% CI) 1.07 [-2.42, 4.57]
4.2 Children 2 48 Mean Difference (IV, Fixed, 95% CI) 0.92 [-4.96, 6.79]
5 30 minute rise in FEV1 (%
predicted)
3 200 Mean Difference (IV, Fixed, 95% CI) -0.20 [-3.18, 2.78]
5.1 Adults 3 200 Mean Difference (IV, Fixed, 95% CI) -0.20 [-3.18, 2.78]
6 Severe asthmatics final rise in
FEV1 (% predicted)
4 94 Mean Difference (IV, Fixed, 95% CI) 1.60 [-4.49, 7.69]
6.1 Adults 4 94 Mean Difference (IV, Fixed, 95% CI) 1.60 [-4.49, 7.69]
7 Final rise in peak flow (%
predicted)
6 305 Mean Difference (IV, Fixed, 95% CI) -1.31 [-4.68, 2.07]
7.1 Adults 3 139 Mean Difference (IV, Fixed, 95% CI) -0.49 [-4.60, 3.63]
7.2 Children 3 166 Mean Difference (IV, Fixed, 95% CI) -2.99 [-8.88, 2.91]
8 30 minute rise in peak flow (%
predicted)
2 147 Mean Difference (IV, Fixed, 95% CI) 0.92 [-2.68, 4.51]
8.1 Adults 2 147 Mean Difference (IV, Fixed, 95% CI) 0.92 [-2.68, 4.51]
9 Rise in pulse rate (% baseline) 15 996 Mean Difference (IV, Fixed, 95% CI) -4.57 [-6.22, -2.93]
9.1 Adults 7 376 Mean Difference (IV, Fixed, 95% CI) -1.23 [-4.06, 1.60]
9.2 Children 8 620 Mean Difference (IV, Fixed, 95% CI) -6.27 [-8.29, -4.25]
10 Number of patients developing
tremor
6 343 Risk Ratio (IV, Fixed, 95% CI) 0.80 [0.58, 1.10]
10.1 Adults 4 234 Risk Ratio (IV, Fixed, 95% CI) 1.12 [0.66, 1.90]
10.2 Children 2 109 Risk Ratio (IV, Fixed, 95% CI) 0.65 [0.43, 0.98]
11 Number of patients given
steroids
3 240 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.81, 1.54]
11.1 Adults 2 88 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.23, 2.13]
11.2 Children 1 152 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.87, 1.67]
12 Rise in respiratory rate (breaths
per minute)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Adults 5 257 Mean Difference (IV, Random, 95% CI) 0.28 [-2.29, 2.84]
12.2 Children 6 491 Mean Difference (IV, Random, 95% CI) -0.68 [-2.81, 1.44]
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13 % Oxygen Saturation (change
from baseline)
4 281 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.76, 0.45]
13.1 Adults 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
13.2 Children 4 281 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.76, 0.45]
Comparison 2. Spacer (chamber) versus Nebuliser (Single treatment studies)




participants Statistical method Effect size
1 Hospital admission 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Adults 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 Children 3 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Final rise in peak flow (%
predicted)
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.1 Adults 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 Children 0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 30 minute rise in FEV1 (%
predicted)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Adults 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 15 minute rise in FEV1 (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 30 minute rise in peak flow (%
predicted)
3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Adults 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5.2 Children 2 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 15 minute rise in peak flow (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 Rise in pulse rate (% baseline) 3 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Adults 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.2 Children 2 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Number of patients developing
tremor
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Children 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
9 Number of patients with
deterioration in blood gases
2 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 Children 2 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Rise in respiratory rate 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Adults 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
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Comparison 3. Spacer (chamber) versus Nebuliser (Inpatient studies)




participants Statistical method Effect size
1 Duration of hospital admission
(days)
2 78 Mean Difference (IV, Fixed, 95% CI) 0.26 [-0.23, 0.75]
1.1 Adults 1 18 Mean Difference (IV, Fixed, 95% CI) -0.60 [-3.23, 2.03]
1.2 Children 1 60 Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.21, 0.79]
2 Number of hours until reached
4 hourly dosing regime
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Total number of inhaled doses
received
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Number of patients returning to
normal PEFR and respiratory
score levels (end of study)
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Adults 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4.2 Children 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Number of symptom-free
patients 14 days post discharge
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Adults 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Children 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Readmissions in the subsequent
12 months
1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Adults 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 Children 1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Clinical asthma score (end of
trial)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
7.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Maximum percentage decrease
in respiratory score
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
8.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9 Respiratory rate at discharge 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
9.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10 Heart rate at discharge 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
10.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
11 Oxygen Saturations at
discharge
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
11.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12 30 minute rise in FEV1 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Adults 1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
12.2 Children 1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
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13 Final rise in FEV1 2 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 Adults 1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
13.2 Children 1 Std. Mean Difference (IV, Fixed, 95% CI) Not estimable
14 Final rise in peak flow (%
change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 Adults 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
14.2 Children 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 4. Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)




participants Statistical method Effect size
1 Hospital admission 13 857 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.60, 1.14]
1.1 Adults 5 308 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.60, 3.53]
1.2 Adults with Volumatic 2 166 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.51, 1.38]
1.3 Children 5 365 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.40, 1.06]
1.4 Children with Volumatic 1 18 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Hospital admission or poor
response to treatment
15 987 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.68, 1.22]
2.1 Adults 5 308 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.60, 3.53]
2.2 Adults with Volumatic 2 166 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.51, 1.38]
2.3 Children 6 435 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.51, 1.23]
2.4 Children with Volumatic 2 78 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.44, 3.06]
3 Duration in emergency
department (hours).
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Adults 1 35 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.77, 0.37]
3.2 Adults with Volumatic 1 97 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.34, 0.94]
3.3 Children 2 348 Mean Difference (IV, Fixed, 95% CI) -0.47 [-0.58, -0.37]
4 Final rise in FEV1 (% predicted) 7 335 Mean Difference (IV, Fixed, 95% CI) 0.78 [-2.32, 3.87]
4.1 Adults 3 168 Mean Difference (IV, Fixed, 95% CI) 0.30 [-4.70, 5.30]
4.2 Adults with Volumatic 2 119 Mean Difference (IV, Fixed, 95% CI) 1.20 [-4.13, 6.53]
4.3 Children 1 30 Mean Difference (IV, Fixed, 95% CI) Not estimable
4.4 Children with Volumatic 1 18 Mean Difference (IV, Fixed, 95% CI) 9.8 [-9.41, 29.01]
5 30 minute rise in FEV1 (%
predicted)
2 150 Mean Difference (IV, Fixed, 95% CI) -1.07 [-4.35, 2.21]
5.1 Adults 1 53 Mean Difference (IV, Fixed, 95% CI) -3.80 [-8.51, 0.91]
5.2 Adults with Volumatic 1 97 Mean Difference (IV, Fixed, 95% CI) 1.5 [-3.07, 6.07]
6 Severe asthmatics final rise in
FEV1 (% predicted)
4 94 Mean Difference (IV, Fixed, 95% CI) 1.60 [-4.49, 7.69]
6.1 Adults 3 55 Mean Difference (IV, Fixed, 95% CI) 0.86 [-6.77, 8.48]
6.2 Adults with Volumatic 1 39 Mean Difference (IV, Fixed, 95% CI) 2.90 [-7.21, 13.01]
7 Final rise in peak flow (%
predicted)
5 285 Mean Difference (IV, Fixed, 95% CI) -1.32 [-4.83, 2.20]
7.1 Adults with Volumatic 2 119 Mean Difference (IV, Fixed, 95% CI) -0.39 [-4.77, 3.98]
7.2 Children 2 148 Mean Difference (IV, Fixed, 95% CI) -3.75 [-9.95, 2.45]
7.3 Children with Volumatic 1 18 Mean Difference (IV, Fixed, 95% CI) 4.10 [-14.81, 23.01]
8 30 minute rise in peak flow (%
predicted)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
56Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
8.1 Adults with Volumatic 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9 Rise in pulse rate (% baseline) 12 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 Adults 3 168 Mean Difference (IV, Fixed, 95% CI) -2.28 [-7.81, 3.24]
9.2 Adults with Volumatic 3 188 Mean Difference (IV, Fixed, 95% CI) -0.16 [-3.89, 3.58]
9.3 Children 4 314 Mean Difference (IV, Fixed, 95% CI) -8.30 [-10.93, -5.67]
9.4 Children with Volumatic 2 78 Mean Difference (IV, Fixed, 95% CI) -6.73 [-11.24, -2.23]
Analysis 1.1. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 1
Hospital admission.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 1 Hospital admission
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Colacone 1993 1/40 0/40 3.00 [ 0.13, 71.51 ]
Idris 1993 1/15 1/20 1.33 [ 0.09, 19.64 ]
Raimondi 1997 0/9 0/9 0.0 [ 0.0, 0.0 ]
Rao 2002 0/25 1/25 0.33 [ 0.01, 7.81 ]
Rodrigo 1993 5/49 4/48 1.22 [ 0.35, 4.29 ]
Rodriguez 1999 14/36 17/33 0.75 [ 0.45, 1.28 ]
Turner 1988 4/27 5/26 0.77 [ 0.23, 2.56 ]
Vivek 2003 5/68 1/54 3.97 [ 0.48, 32.98 ]
Subtotal (95% CI) 269 255 0.97 [ 0.63, 1.49 ]
Total events: 30 (Holding Chamber), 29 (Nebuliser)
Heterogeneity: Chi2 = 3.82, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Children
Chong-Neto 2005 0/20 0/10 0.0 [ 0.0, 0.0 ]
Chou 1995 4/71 5/81 0.91 [ 0.25, 3.27 ]
Jamalvi 2006 4/84 7/66 0.45 [ 0.14, 1.47 ]
Leversha 2000 10/30 18/30 0.56 [ 0.31, 1.00 ]
Ploin 2000 3/31 3/32 1.03 [ 0.23, 4.73 ]
Sannier 2007 6/39 3/40 2.05 [ 0.55, 7.63 ]
Vazquez 1992 0/9 0/9 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Chamber better Nebuliser better
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(. . . Continued)
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Williams 1996 2/42 2/18 0.43 [ 0.07, 2.81 ]
Subtotal (95% CI) 326 286 0.72 [ 0.47, 1.09 ]
Total events: 29 (Holding Chamber), 38 (Nebuliser)
Heterogeneity: Chi2 = 4.43, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
Total (95% CI) 595 541 0.83 [ 0.61, 1.12 ]
Total events: 59 (Holding Chamber), 67 (Nebuliser)
Heterogeneity: Chi2 = 8.90, df = 12 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
0.01 0.1 1 10 100
Chamber better Nebuliser better
Analysis 1.2. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 2
Hospital admission or poor response to treatment.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 2 Hospital admission or poor response to treatment
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Colacone 1993 1/40 0/40 3.00 [ 0.13, 71.51 ]
Idris 1993 1/15 1/20 1.33 [ 0.09, 19.64 ]
Raimondi 1997 0/9 0/9 0.0 [ 0.0, 0.0 ]
Rao 2002 0/25 1/25 0.33 [ 0.01, 7.81 ]
Rodrigo 1993 5/49 4/48 1.22 [ 0.35, 4.29 ]
Rodriguez 1999 14/36 17/33 0.75 [ 0.45, 1.28 ]
Turner 1988 4/27 5/26 0.77 [ 0.23, 2.56 ]
Vivek 2003 5/68 1/54 3.97 [ 0.48, 32.98 ]
Subtotal (95% CI) 269 255 0.97 [ 0.63, 1.49 ]
Total events: 30 (Holding Chamber), 29 (Nebuliser)
0.01 0.1 1 10 100
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(. . . Continued)
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 3.82, df = 6 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Children
Batra 1997 7/30 6/30 1.17 [ 0.44, 3.06 ]
Chong-Neto 2005 0/20 0/10 0.0 [ 0.0, 0.0 ]
Chou 1995 4/71 5/81 0.91 [ 0.25, 3.27 ]
Jamalvi 2006 4/84 7/66 0.45 [ 0.14, 1.47 ]
Leversha 2000 10/30 18/30 0.56 [ 0.31, 1.00 ]
Ploin 2000 3/31 3/32 1.03 [ 0.23, 4.73 ]
Sannier 2007 6/39 3/40 2.05 [ 0.55, 7.63 ]
Valencia 1999 7/32 5/38 1.66 [ 0.58, 4.74 ]
Vazquez 1992 0/9 0/9 0.0 [ 0.0, 0.0 ]
Williams 1996 2/42 2/18 0.43 [ 0.07, 2.81 ]
Subtotal (95% CI) 388 354 0.86 [ 0.60, 1.23 ]
Total events: 43 (Holding Chamber), 49 (Nebuliser)
Heterogeneity: Chi2 = 7.47, df = 7 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.84 (P = 0.40)
Total (95% CI) 657 609 0.90 [ 0.68, 1.18 ]
Total events: 73 (Holding Chamber), 78 (Nebuliser)
Heterogeneity: Chi2 = 11.30, df = 14 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 1.3. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 3
Duration in emergency department (hours)..
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 3 Duration in emergency department (hours).





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Idris 1993 15 1.5 (0.8) 20 1.7 (0.9) 56.0 % -0.20 [ -0.77, 0.37 ]
Rodrigo 1993 49 2.2 (1.7) 48 1.9 (1.5) 44.0 % 0.30 [ -0.34, 0.94 ]
Subtotal (95% CI) 64 68 100.0 % 0.02 [ -0.40, 0.44 ]
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Children
Chou 1995 71 1.1 (0.52) 81 1.72 (0.86) 15.8 % -0.62 [ -0.84, -0.40 ]
Duarte 2002 97 0.69 (0.3) 99 1.12 (0.52) 55.9 % -0.43 [ -0.55, -0.31 ]
Sannier 2007 28 1.8 (0.217) 20 2.47 (0.333) 28.3 % -0.67 [ -0.84, -0.50 ]
Subtotal (95% CI) 196 200 100.0 % -0.53 [ -0.62, -0.44 ]
Heterogeneity: Chi2 = 6.07, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 11.67 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.18, df = 1 (P = 0.01), I2 =84%
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Analysis 1.4. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 4
Final rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 4 Final rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Colacone 1993 40 23 (16) 40 22 (19) 15.2 % 1.00 [ -6.70, 8.70 ]
Idris 1993 15 27.1 (12.7) 20 26.4 (20.4) 7.4 % 0.70 [ -10.31, 11.71 ]
Rao 2002 8 22.7 (14.21) 12 17.58 (13.18) 5.9 % 5.12 [ -7.23, 17.47 ]
Rodrigo 1993 49 25 (15.6) 48 23 (12.7) 28.2 % 2.00 [ -3.66, 7.66 ]
Rodrigo 1998 11 44.3 (16.7) 11 49.4 (21) 3.6 % -5.10 [ -20.96, 10.76 ]
Turner 1988 27 13.03 (13.88) 26 13.74 (16.41) 13.4 % -0.71 [ -8.91, 7.49 ]
Subtotal (95% CI) 150 157 73.8 % 1.07 [ -2.42, 4.57 ]
Heterogeneity: Chi2 = 1.28, df = 5 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Children
Chong-Neto 2005 20 34 (10) 10 34 (7) 23.7 % 0.0 [ -6.17, 6.17 ]
Vazquez 1992 9 29.5 (23.4) 9 19.7 (17.8) 2.4 % 9.80 [ -9.41, 29.01 ]
Subtotal (95% CI) 29 19 26.2 % 0.92 [ -4.96, 6.79 ]
Heterogeneity: Chi2 = 0.91, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
Total (95% CI) 179 176 100.0 % 1.03 [ -1.97, 4.04 ]
Heterogeneity: Chi2 = 2.19, df = 7 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.96), I2 =0.0%
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Analysis 1.5. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 5 30
minute rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 5 30 minute rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Rao 2002 25 19.56 (11.27) 25 15.6 (14.39) 17.3 % 3.96 [ -3.20, 11.12 ]
Rodrigo 1993 49 17 (13.5) 48 15.5 (9.1) 42.6 % 1.50 [ -3.07, 6.07 ]
Turner 1988 27 5.4 (7.5) 26 9.2 (9.8) 40.1 % -3.80 [ -8.51, 0.91 ]
Total (95% CI) 101 99 100.0 % -0.20 [ -3.18, 2.78 ]
Heterogeneity: Chi2 = 4.07, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 6
Severe asthmatics final rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 6 Severe asthmatics final rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Idris 1993 6 26 (20) 8 14 (18) 9.0 % 12.00 [ -8.29, 32.29 ]
Raimondi 1997 9 29 (15) 9 27 (15) 19.3 % 2.00 [ -11.86, 15.86 ]
Rodrigo 1993 19 22.6 (17.5) 20 19.7 (14.5) 36.2 % 2.90 [ -7.21, 13.01 ]
Turner 1988 10 9.52 (11.01) 13 12.12 (14.02) 35.4 % -2.60 [ -12.83, 7.63 ]
Total (95% CI) 44 50 100.0 % 1.60 [ -4.49, 7.69 ]
Heterogeneity: Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 7
Final rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 7 Final rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Rao 2002 8 14.24 (15.56) 12 15.43 (9.69) 7.8 % -1.19 [ -13.29, 10.91 ]
Rodrigo 1993 49 22.1 (13) 48 21.4 (10) 53.6 % 0.70 [ -3.91, 5.31 ]
Rodrigo 1998 11 47.5 (14.4) 11 57.9 (18.7) 5.9 % -10.40 [ -24.35, 3.55 ]
Subtotal (95% CI) 68 71 67.2 % -0.49 [ -4.60, 3.63 ]
Heterogeneity: Chi2 = 2.21, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Children
Chou 1995 39 19 (19.5) 49 25 (19.1) 17.2 % -6.00 [ -14.13, 2.13 ]
Vazquez 1992 9 29.6 (21.4) 9 25.5 (19.5) 3.2 % 4.10 [ -14.81, 23.01 ]
Williams 1996 42 25 (18.2) 18 25.61 (17) 12.4 % -0.61 [ -10.20, 8.98 ]
Subtotal (95% CI) 90 76 32.8 % -2.99 [ -8.88, 2.91 ]
Heterogeneity: Chi2 = 1.30, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
Total (95% CI) 158 147 100.0 % -1.31 [ -4.68, 2.07 ]
Heterogeneity: Chi2 = 3.98, df = 5 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Chi2 = 0.46, df = 1 (P = 0.50), I2 =0.0%
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Analysis 1.8. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 8 30
minute rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 8 30 minute rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Rao 2002 25 14.24 (13.94) 25 12.52 (14.24) 21.2 % 1.72 [ -6.09, 9.53 ]
Rodrigo 1993 49 15.4 (11.4) 48 14.7 (8.8) 78.8 % 0.70 [ -3.35, 4.75 ]
Total (95% CI) 74 73 100.0 % 0.92 [ -2.68, 4.51 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 9
Rise in pulse rate (% baseline).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 9 Rise in pulse rate (% baseline)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Colacone 1993 40 -1 (19) 40 4 (19) 3.9 % -5.00 [ -13.33, 3.33 ]
Idris 1993 15 1 (16) 20 0 (18) 2.1 % 1.00 [ -10.30, 12.30 ]
Rao 2002 8 -15.91 (6.95) 12 -12.58 (9.02) 5.5 % -3.33 [ -10.35, 3.69 ]
Rodrigo 1993 49 -1.32 (13.8) 48 -0.44 (14.2) 8.7 % -0.88 [ -6.45, 4.69 ]
Rodrigo 1998 11 -10 (19.7) 11 -2 (19.7) 1.0 % -8.00 [ -24.46, 8.46 ]
Rodriguez 1999 36 0 (11.7) 33 -1.3 (10.7) 9.7 % 1.30 [ -3.99, 6.59 ]
Turner 1988 27 -4 (16) 26 -3 (20) 2.8 % -1.00 [ -10.77, 8.77 ]
Subtotal (95% CI) 186 190 33.7 % -1.23 [ -4.06, 1.60 ]
Heterogeneity: Chi2 = 2.83, df = 6 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
2 Children
Batra 1997 30 -12.8 (9.4) 30 -7.4 (11.6) 9.5 % -5.40 [ -10.74, -0.06 ]
Chong-Neto 2005 20 20.6 (10.4) 10 32.9 (12.2) 3.5 % -12.30 [ -21.13, -3.47 ]
Chou 1995 71 5 (12.4) 81 15 (17.3) 12.0 % -10.00 [ -14.74, -5.26 ]
Duarte 2002 34 15 (20.7) 38 20 (18.1) 3.3 % -5.00 [ -14.03, 4.03 ]
Jamalvi 2006 84 -18 (16.4) 66 -17 (15.7) 10.2 % -1.00 [ -6.16, 4.16 ]
Leversha 2000 30 0.11 (7.2) 30 7.26 (7.2) 20.4 % -7.15 [ -10.79, -3.51 ]
Sannier 2007 39 22.8 (24.7) 39 20.2 (12.4) 3.6 % 2.60 [ -6.07, 11.27 ]
Vazquez 1992 9 -10 (10) 9 0 (8) 3.9 % -10.00 [ -18.37, -1.63 ]
Subtotal (95% CI) 317 303 66.3 % -6.27 [ -8.29, -4.25 ]
Heterogeneity: Chi2 = 13.35, df = 7 (P = 0.06); I2 =48%
Test for overall effect: Z = 6.09 (P < 0.00001)
Total (95% CI) 503 493 100.0 % -4.57 [ -6.22, -2.93 ]
Heterogeneity: Chi2 = 24.25, df = 14 (P = 0.04); I2 =42%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Chi2 = 8.07, df = 1 (P = 0.00), I2 =88%
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Analysis 1.10. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 10
Number of patients developing tremor.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 10 Number of patients developing tremor
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Colacone 1993 3/40 3/40 1.00 [ 0.21, 4.66 ]
Idris 1993 0/15 0/20 0.0 [ 0.0, 0.0 ]
Rodrigo 1993 18/49 13/48 1.36 [ 0.75, 2.45 ]
Rodrigo 1998 1/11 6/11 0.17 [ 0.02, 1.17 ]
Subtotal (95% CI) 115 119 1.12 [ 0.66, 1.90 ]
Total events: 22 (Holding Chamber), 22 (Nebuliser)
Heterogeneity: Chi2 = 4.11, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Children
Chong-Neto 2005 12/20 9/10 0.67 [ 0.44, 1.01 ]
Sannier 2007 1/39 3/40 0.34 [ 0.04, 3.15 ]
Subtotal (95% CI) 59 50 0.65 [ 0.43, 0.98 ]
Total events: 13 (Holding Chamber), 12 (Nebuliser)
Heterogeneity: Chi2 = 0.34, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.06 (P = 0.039)
Total (95% CI) 174 169 0.80 [ 0.58, 1.10 ]
Total events: 35 (Holding Chamber), 34 (Nebuliser)
Heterogeneity: Chi2 = 6.94, df = 4 (P = 0.14); I2 =42%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 2.50, df = 1 (P = 0.11), I2 =60%
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Analysis 1.11. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 11
Number of patients given steroids.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 11 Number of patients given steroids
Study or subgroup Holding Chamber Nebuliser Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Idris 1993 1/15 6/20 12.6 % 0.22 [ 0.03, 1.66 ]
Turner 1988 4/27 2/26 5.0 % 1.93 [ 0.39, 9.63 ]
Subtotal (95% CI) 42 46 17.6 % 0.71 [ 0.23, 2.13 ]
Total events: 5 (Holding Chamber), 8 (Nebuliser)
Heterogeneity: Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.62 (P = 0.54)
2 Children
Chou 1995 38/71 36/81 82.4 % 1.20 [ 0.87, 1.67 ]
Subtotal (95% CI) 71 81 82.4 % 1.20 [ 0.87, 1.67 ]
Total events: 38 (Holding Chamber), 36 (Nebuliser)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 113 127 100.0 % 1.12 [ 0.81, 1.54 ]
Total events: 43 (Holding Chamber), 44 (Nebuliser)
Heterogeneity: Chi2 = 3.13, df = 2 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.68 (P = 0.50)
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Analysis 1.12. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 12
Rise in respiratory rate (breaths per minute).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 12 Rise in respiratory rate (breaths per minute)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Adults
Colacone 1993 40 -3 (6.3) 40 -3 (7.6) 19.5 % 0.0 [ -3.06, 3.06 ]
Idris 1993 15 -5 (4) 20 -2 (6) 18.4 % -3.00 [ -6.32, 0.32 ]
Rao 2002 8 -8.62 (3.38) 12 -6.23 (3.39) 19.6 % -2.39 [ -5.42, 0.64 ]
Rodriguez 1999 36 -3.3 (5.5) 33 -6.5 (5.2) 21.8 % 3.20 [ 0.68, 5.72 ]
Turner 1988 27 -3 (5.2) 26 -6 (5.1) 20.7 % 3.00 [ 0.23, 5.77 ]
Subtotal (95% CI) 126 131 100.0 % 0.28 [ -2.29, 2.84 ]
Heterogeneity: Tau2 = 6.29; Chi2 = 15.37, df = 4 (P = 0.004); I2 =74%
Test for overall effect: Z = 0.21 (P = 0.83)
2 Children
Batra 1997 30 -23.5 (6.7) 30 -20.9 (7.4) 17.9 % -2.60 [ -6.17, 0.97 ]
Duarte 2002 34 -6 (4.1) 38 -4 (5.9) 23.4 % -2.00 [ -4.33, 0.33 ]
Jamalvi 2006 84 -22 (9.2) 66 -19 (10.9) 19.1 % -3.00 [ -6.28, 0.28 ]
Leversha 2000 30 0.13 (8) 30 -1.21 (8) 16.1 % 1.34 [ -2.71, 5.39 ]
Sannier 2007 39 -1.14 (9) 40 -5.05 (9.9) 15.6 % 3.91 [ -0.26, 8.08 ]
Valencia 1999 32 -3.13 (16.4) 38 -4.07 (14.34) 7.8 % 0.94 [ -6.35, 8.23 ]
Subtotal (95% CI) 249 242 100.0 % -0.68 [ -2.81, 1.44 ]
Heterogeneity: Tau2 = 3.28; Chi2 = 9.78, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 1.13. Comparison 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies), Outcome 13
% Oxygen Saturation (change from baseline).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 1 Spacer (chamber) versus Nebuliser (Multiple treatment studies)
Outcome: 13 % Oxygen Saturation (change from baseline)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Children
Duarte 2002 34 1.5 (2.5) 38 1.2 (6.3) 7.8 % 0.30 [ -1.87, 2.47 ]
Leversha 2000 30 0.67 (2.35) 30 1 (2.35) 25.9 % -0.33 [ -1.52, 0.86 ]
Sannier 2007 39 1.2 (1.5) 40 1.4 (2.1) 56.8 % -0.20 [ -1.00, 0.60 ]
Valencia 1999 32 1.71 (4.46) 38 1.45 (3.84) 9.5 % 0.26 [ -1.71, 2.23 ]
Subtotal (95% CI) 135 146 100.0 % -0.15 [ -0.76, 0.45 ]
Heterogeneity: Chi2 = 0.43, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Total (95% CI) 135 146 100.0 % -0.15 [ -0.76, 0.45 ]
Heterogeneity: Chi2 = 0.43, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Nebuliser better Chamber better
70Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 1
Hospital admission.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 1 Hospital admission
Study or subgroup Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Salzman 1989 6/24 3/20 1.67 [ 0.48, 5.83 ]
2 Children
Freelander 1984 1/14 3/14 0.33 [ 0.04, 2.83 ]
Hussein 2002 3/30 4/30 0.75 [ 0.18, 3.07 ]
Kerem 1993 5/17 6/16 0.78 [ 0.30, 2.07 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 2.3. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 3 30
minute rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 3 30 minute rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Salzman 1989 24 12.8 (13.2) 20 11 (15.2) 1.80 [ -6.70, 10.30 ]
2 Children
Kerem 1993 17 8 (10.15) 16 4.93 (9.12) 3.07 [ -3.51, 9.65 ]
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Analysis 2.4. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 4 15
minute rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 4 15 minute rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Children
Lin 1995 56 13.06 (13) 55 8.66 (9) 4.40 [ 0.25, 8.55 ]
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Analysis 2.5. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 5 30
minute rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 5 30 minute rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Morrone 1990 22 16 (13) 22 16 (13) 0.0 [ -7.68, 7.68 ]
2 Children
Freelander 1984 11 20 (27) 6 20 (25) 0.0 [ -25.59, 25.59 ]
Robertson 1998 29 9 (22) 30 21 (33) -12.00 [ -26.27, 2.27 ]
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Analysis 2.6. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 6 15
minute rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 6 15 minute rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Children
Lin 1995 56 12.54 (20) 55 2.49 (8) 10.05 [ 4.40, 15.70 ]
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Analysis 2.7. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 7 Rise
in pulse rate (% baseline).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 7 Rise in pulse rate (% baseline)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Salzman 1989 24 -4 (20) 20 -8 (10) 4.00 [ -5.12, 13.12 ]
2 Children
Kerem 1993 17 -6.8 (14.4) 16 11.8 (27.4) -18.60 [ -33.67, -3.53 ]
Lin 1995 56 1 (17) 55 2 (19) -1.00 [ -7.71, 5.71 ]
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Analysis 2.8. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 8
Number of patients developing tremor.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 8 Number of patients developing tremor
Study or subgroup Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
Kerem 1993 1/17 4/16 0.24 [ 0.03, 1.89 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 2.9. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 9
Number of patients with deterioration in blood gases.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 9 Number of patients with deterioration in blood gases
Study or subgroup Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children
Kerem 1993 2/17 3/16 0.63 [ 0.12, 3.28 ]
Lin 1995 13/56 26/55 0.49 [ 0.28, 0.85 ]
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Analysis 2.10. Comparison 2 Spacer (chamber) versus Nebuliser (Single treatment studies), Outcome 10
Rise in respiratory rate.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 2 Spacer (chamber) versus Nebuliser (Single treatment studies)
Outcome: 10 Rise in respiratory rate





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Salzman 1989 24 -3 (3.9) 20 -4 (4.2) 1.00 [ -1.41, 3.41 ]
2 Children
Kerem 1993 17 -4.06 (6.38) 16 -4.33 (4.17) 0.27 [ -3.39, 3.93 ]
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Analysis 3.1. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 1 Duration of
hospital admission (days).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 1 Duration of hospital admission (days)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Morley 1988 10 5.8 (2.1) 8 6.4 (3.3) 3.4 % -0.60 [ -3.23, 2.03 ]
Subtotal (95% CI) 10 8 3.4 % -0.60 [ -3.23, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
2 Children
Parkin 1995 30 2.21 (0.98) 30 1.92 (0.98) 96.6 % 0.29 [ -0.21, 0.79 ]
Subtotal (95% CI) 30 30 96.6 % 0.29 [ -0.21, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Total (95% CI) 40 38 100.0 % 0.26 [ -0.23, 0.75 ]
Heterogeneity: Chi2 = 0.42, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.04 (P = 0.30)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.51), I2 =0.0%
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Analysis 3.2. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 2 Number of
hours until reached 4 hourly dosing regime.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 2 Number of hours until reached 4 hourly dosing regime





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Parkin 1995 30 24 (18.07) 30 19 (18.07) 5.00 [ -4.14, 14.14 ]
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Analysis 3.3. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 3 Total
number of inhaled doses received.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 3 Total number of inhaled doses received





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Parkin 1995 30 21 (10.95) 30 17 (10.95) 4.00 [ -1.54, 9.54 ]
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Analysis 3.4. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 4 Number of
patients returning to normal PEFR and respiratory score levels (end of study).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 4 Number of patients returning to normal PEFR and respiratory score levels (end of study)
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
2 Children
Coker 1995 7/12 10/12 0.70 [ 0.41, 1.20 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 3.5. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 5 Number of
symptom-free patients 14 days post discharge.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 5 Number of symptom-free patients 14 days post discharge
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
2 Children
Parkin 1995 19/30 20/30 0.95 [ 0.66, 1.38 ]
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Analysis 3.6. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 6
Readmissions in the subsequent 12 months.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 6 Readmissions in the subsequent 12 months
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
2 Children
Dewar 1999 4/29 9/33 0.51 [ 0.17, 1.47 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 3.7. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 7 Clinical
asthma score (end of trial).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 7 Clinical asthma score (end of trial)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Parkin 1995 30 2 (1.64) 30 2.2 (1.64) -0.20 [ -1.03, 0.63 ]
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Analysis 3.8. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 8 Maximum
percentage decrease in respiratory score.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 8 Maximum percentage decrease in respiratory score





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Coker 1995 12 80.8 (29) 12 89.68 (24.18) -8.88 [ -30.24, 12.48 ]
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Analysis 3.9. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 9 Respiratory
rate at discharge.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 9 Respiratory rate at discharge





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Dewar 1999 29 26.6 (5.25) 33 27.2 (5.17) -0.60 [ -3.20, 2.00 ]
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Analysis 3.10. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 10 Heart
rate at discharge.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 10 Heart rate at discharge





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Dewar 1999 29 101.2 (12.39) 33 99.3 (15.08) 1.90 [ -4.94, 8.74 ]
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Analysis 3.11. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 11 Oxygen
Saturations at discharge.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 11 Oxygen Saturations at discharge





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Dewar 1999 29 96.4 (1.35) 33 96.1 (0.86) 0.30 [ -0.27, 0.87 ]
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Analysis 3.12. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 12 30
minute rise in FEV1.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 12 30 minute rise in FEV1







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Morley 1988 10 1.92 (0.78) 8 1.72 (1) 0.22 [ -0.72, 1.15 ]
2 Children
Ba 1989 14 34.5 (9) 13 23.5 (3.5) 1.54 [ 0.66, 2.42 ]
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Analysis 3.13. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 13 Final rise
in FEV1.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 13 Final rise in FEV1







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Morley 1988 10 1.87 (0.96) 8 1.46 (0.64) 0.47 [ -0.48, 1.41 ]
2 Children
Ba 1989 14 26 (9) 13 11.5 (5.5) 1.87 [ 0.94, 2.80 ]
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Analysis 3.14. Comparison 3 Spacer (chamber) versus Nebuliser (Inpatient studies), Outcome 14 Final rise
in peak flow (% change from baseline).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 3 Spacer (chamber) versus Nebuliser (Inpatient studies)
Outcome: 14 Final rise in peak flow (% change from baseline)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
2 Children
Coker 1995 12 100.62 (79.55) 12 105.43 (53.79) -4.81 [ -59.14, 49.52 ]
-10 -5 0 5 10
Favours Nebuliser Favours Chamber
Analysis 4.1. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 1 Hospital admission.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 1 Hospital admission
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Colacone 1993 1/40 0/40 3.00 [ 0.13, 71.51 ]
Idris 1993 1/15 1/20 1.33 [ 0.09, 19.64 ]
Raimondi 1997 0/9 0/9 0.0 [ 0.0, 0.0 ]
Turner 1988 4/27 5/26 0.77 [ 0.23, 2.56 ]
Vivek 2003 5/68 1/54 3.97 [ 0.48, 32.98 ]
Subtotal (95% CI) 159 149 1.45 [ 0.60, 3.53 ]
Total events: 11 (Holding Chamber), 7 (Nebuliser)
Heterogeneity: Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
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(. . . Continued)
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
2 Adults with Volumatic
Rodrigo 1993 5/49 4/48 1.22 [ 0.35, 4.29 ]
Rodriguez 1999 14/36 17/33 0.75 [ 0.45, 1.28 ]
Subtotal (95% CI) 85 81 0.84 [ 0.51, 1.38 ]
Total events: 19 (Holding Chamber), 21 (Nebuliser)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
3 Children
Chong-Neto 2005 0/20 0/10 0.0 [ 0.0, 0.0 ]
Chou 1995 4/71 5/81 0.91 [ 0.25, 3.27 ]
Leversha 2000 10/30 18/30 0.56 [ 0.31, 1.00 ]
Ploin 2000 3/31 3/32 1.03 [ 0.23, 4.73 ]
Williams 1996 2/42 2/18 0.43 [ 0.07, 2.81 ]
Subtotal (95% CI) 194 171 0.65 [ 0.40, 1.06 ]
Total events: 19 (Holding Chamber), 28 (Nebuliser)
Heterogeneity: Chi2 = 1.09, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.71 (P = 0.087)
4 Children with Volumatic
Vazquez 1992 0/9 0/9 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 9 9 0.0 [ 0.0, 0.0 ]
Total events: 0 (Holding Chamber), 0 (Nebuliser)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 447 410 0.83 [ 0.60, 1.14 ]
Total events: 49 (Holding Chamber), 56 (Nebuliser)
Heterogeneity: Chi2 = 5.73, df = 9 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.14 (P = 0.25)
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Analysis 4.2. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 2 Hospital admission or poor response to treatment.
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 2 Hospital admission or poor response to treatment
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults
Colacone 1993 1/40 0/40 3.00 [ 0.13, 71.51 ]
Idris 1993 1/15 1/20 1.33 [ 0.09, 19.64 ]
Raimondi 1997 0/9 0/9 0.0 [ 0.0, 0.0 ]
Turner 1988 4/27 5/26 0.77 [ 0.23, 2.56 ]
Vivek 2003 5/68 1/54 3.97 [ 0.48, 32.98 ]
Subtotal (95% CI) 159 149 1.45 [ 0.60, 3.53 ]
Total events: 11 (Holding Chamber), 7 (Nebuliser)
Heterogeneity: Chi2 = 2.15, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Adults with Volumatic
Rodrigo 1993 5/49 4/48 1.22 [ 0.35, 4.29 ]
Rodriguez 1999 14/36 17/33 0.75 [ 0.45, 1.28 ]
Subtotal (95% CI) 85 81 0.84 [ 0.51, 1.38 ]
Total events: 19 (Holding Chamber), 21 (Nebuliser)
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.49)
3 Children
Chong-Neto 2005 0/20 0/10 0.0 [ 0.0, 0.0 ]
Chou 1995 4/71 5/81 0.91 [ 0.25, 3.27 ]
Leversha 2000 10/30 18/30 0.56 [ 0.31, 1.00 ]
Ploin 2000 3/31 3/32 1.03 [ 0.23, 4.73 ]
Valencia 1999 7/32 5/38 1.66 [ 0.58, 4.74 ]
Williams 1996 2/42 2/18 0.43 [ 0.07, 2.81 ]
Subtotal (95% CI) 226 209 0.79 [ 0.51, 1.23 ]
Total events: 26 (Holding Chamber), 33 (Nebuliser)
Heterogeneity: Chi2 = 3.91, df = 4 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.05 (P = 0.29)
4 Children with Volumatic
Batra 1997 7/30 6/30 1.17 [ 0.44, 3.06 ]
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(. . . Continued)
Study or subgroup Holding Chamber Nebuliser Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Vazquez 1992 0/9 0/9 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 39 39 1.17 [ 0.44, 3.06 ]
Total events: 7 (Holding Chamber), 6 (Nebuliser)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
Total (95% CI) 509 478 0.91 [ 0.68, 1.22 ]
Total events: 63 (Holding Chamber), 67 (Nebuliser)
Heterogeneity: Chi2 = 8.19, df = 11 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 4.3. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 3 Duration in emergency department (hours)..
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 3 Duration in emergency department (hours).





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Idris 1993 15 1.5 (0.8) 20 1.7 (0.9) 100.0 % -0.20 [ -0.77, 0.37 ]
Subtotal (95% CI) 15 20 100.0 % -0.20 [ -0.77, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Adults with Volumatic
Rodrigo 1993 49 2.2 (1.7) 48 1.9 (1.5) 100.0 % 0.30 [ -0.34, 0.94 ]
Subtotal (95% CI) 49 48 100.0 % 0.30 [ -0.34, 0.94 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
3 Children
Chou 1995 71 1.1 (0.52) 81 1.72 (0.86) 22.0 % -0.62 [ -0.84, -0.40 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Duarte 2002 97 0.69 (0.3) 99 1.12 (0.52) 78.0 % -0.43 [ -0.55, -0.31 ]
Subtotal (95% CI) 168 180 100.0 % -0.47 [ -0.58, -0.37 ]
Heterogeneity: Chi2 = 2.17, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 8.84 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.22, df = 2 (P = 0.04), I2 =68%
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Analysis 4.4. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 4 Final rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 4 Final rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Colacone 1993 40 23 (16) 40 22 (19) 16.2 % 1.00 [ -6.70, 8.70 ]
Idris 1993 15 27.1 (12.7) 20 26.4 (20.4) 7.9 % 0.70 [ -10.31, 11.71 ]
Turner 1988 27 13.03 (13.88) 26 13.74 (16.41) 14.3 % -0.71 [ -8.91, 7.49 ]
Subtotal (95% CI) 82 86 38.4 % 0.30 [ -4.70, 5.30 ]
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
2 Adults with Volumatic
Rodrigo 1993 49 25 (15.6) 48 23 (12.7) 30.0 % 2.00 [ -3.66, 7.66 ]
Rodrigo 1998 11 44.3 (16.7) 11 49.4 (21) 3.8 % -5.10 [ -20.96, 10.76 ]
Subtotal (95% CI) 60 59 33.8 % 1.20 [ -4.13, 6.53 ]
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
3 Children
Chong-Neto 2005 20 34 (10) 10 34 (7) 25.2 % 0.0 [ -6.17, 6.17 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 20 10 25.2 % 0.0 [ -6.17, 6.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 Children with Volumatic
Vazquez 1992 9 29.5 (23.4) 9 19.7 (17.8) 2.6 % 9.80 [ -9.41, 29.01 ]
Subtotal (95% CI) 9 9 2.6 % 9.80 [ -9.41, 29.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 171 164 100.0 % 0.78 [ -2.32, 3.87 ]
Heterogeneity: Chi2 = 1.75, df = 6 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
Test for subgroup differences: Chi2 = 0.97, df = 3 (P = 0.81), I2 =0.0%
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Analysis 4.5. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 5 30 minute rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 5 30 minute rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Turner 1988 27 5.4 (7.5) 26 9.2 (9.8) 48.5 % -3.80 [ -8.51, 0.91 ]
Subtotal (95% CI) 27 26 48.5 % -3.80 [ -8.51, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
2 Adults with Volumatic
Rodrigo 1993 49 17 (13.5) 48 15.5 (9.1) 51.5 % 1.50 [ -3.07, 6.07 ]
Subtotal (95% CI) 49 48 51.5 % 1.50 [ -3.07, 6.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Total (95% CI) 76 74 100.0 % -1.07 [ -4.35, 2.21 ]
Heterogeneity: Chi2 = 2.50, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi2 = 2.50, df = 1 (P = 0.11), I2 =60%
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Analysis 4.6. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 6 Severe asthmatics final rise in FEV1 (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 6 Severe asthmatics final rise in FEV1 (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Idris 1993 6 26 (20) 8 14 (18) 9.0 % 12.00 [ -8.29, 32.29 ]
Raimondi 1997 9 29 (15) 9 27 (15) 19.3 % 2.00 [ -11.86, 15.86 ]
Turner 1988 10 9.52 (11.01) 13 12.12 (14.02) 35.4 % -2.60 [ -12.83, 7.63 ]
Subtotal (95% CI) 25 30 63.8 % 0.86 [ -6.77, 8.48 ]
Heterogeneity: Chi2 = 1.62, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.22 (P = 0.83)
2 Adults with Volumatic
Rodrigo 1993 19 22.6 (17.5) 20 19.7 (14.5) 36.2 % 2.90 [ -7.21, 13.01 ]
Subtotal (95% CI) 19 20 36.2 % 2.90 [ -7.21, 13.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 44 50 100.0 % 1.60 [ -4.49, 7.69 ]
Heterogeneity: Chi2 = 1.72, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Chi2 = 0.10, df = 1 (P = 0.75), I2 =0.0%
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Analysis 4.7. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 7 Final rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 7 Final rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults with Volumatic
Rodrigo 1993 49 22.1 (13) 48 21.4 (10) 58.1 % 0.70 [ -3.91, 5.31 ]
Rodrigo 1998 11 47.5 (14.4) 11 57.9 (18.7) 6.3 % -10.40 [ -24.35, 3.55 ]
Subtotal (95% CI) 60 59 64.4 % -0.39 [ -4.77, 3.98 ]
Heterogeneity: Chi2 = 2.19, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 0.18 (P = 0.86)
2 Children
Chou 1995 39 19 (19.5) 49 25 (19.1) 18.7 % -6.00 [ -14.13, 2.13 ]
Williams 1996 42 25 (18.2) 18 25.61 (17) 13.4 % -0.61 [ -10.20, 8.98 ]
Subtotal (95% CI) 81 67 32.1 % -3.75 [ -9.95, 2.45 ]
Heterogeneity: Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
3 Children with Volumatic
Vazquez 1992 9 29.6 (21.4) 9 25.5 (19.5) 3.5 % 4.10 [ -14.81, 23.01 ]
Subtotal (95% CI) 9 9 3.5 % 4.10 [ -14.81, 23.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
Total (95% CI) 150 135 100.0 % -1.32 [ -4.83, 2.20 ]
Heterogeneity: Chi2 = 3.98, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Chi2 = 1.08, df = 2 (P = 0.58), I2 =0.0%
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Analysis 4.8. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 8 30 minute rise in peak flow (% predicted).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 8 30 minute rise in peak flow (% predicted)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults with Volumatic
Rodrigo 1993 49 15.4 (11.4) 48 14.7 (8.8) 0.70 [ -3.35, 4.75 ]
-10 -5 0 5 10
Nebuliser better Chamber better
Analysis 4.9. Comparison 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic
Subgroups), Outcome 9 Rise in pulse rate (% baseline).
Review: Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma
Comparison: 4 Spacer (chamber) versus Nebuliser (Multiple treatment studies with Volumatic Subgroups)
Outcome: 9 Rise in pulse rate (% baseline)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults
Colacone 1993 40 -1 (19) 40 4 (19) 44.1 % -5.00 [ -13.33, 3.33 ]
Idris 1993 15 1 (16) 20 0 (18) 23.9 % 1.00 [ -10.30, 12.30 ]
Turner 1988 27 -4 (16) 26 -3 (20) 32.0 % -1.00 [ -10.77, 8.77 ]
Subtotal (95% CI) 82 86 100.0 % -2.28 [ -7.81, 3.24 ]
Heterogeneity: Chi2 = 0.80, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Adults with Volumatic
Rodrigo 1993 49 -1.32 (13.8) 48 -0.44 (14.2) 44.9 % -0.88 [ -6.45, 4.69 ]
Rodrigo 1998 11 -10 (19.7) 11 -2 (19.7) 5.1 % -8.00 [ -24.46, 8.46 ]
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N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Rodriguez 1999 36 0 (11.7) 33 -1.3 (10.7) 49.9 % 1.30 [ -3.99, 6.59 ]
Subtotal (95% CI) 96 92 100.0 % -0.16 [ -3.89, 3.58 ]
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.93)
3 Children
Chong-Neto 2005 20 20.6 (10.4) 10 32.9 (12.2) 8.9 % -12.30 [ -21.13, -3.47 ]
Chou 1995 71 5 (12.4) 81 15 (17.3) 30.7 % -10.00 [ -14.74, -5.26 ]
Duarte 2002 34 15 (20.7) 38 20 (18.1) 8.5 % -5.00 [ -14.03, 4.03 ]
Leversha 2000 30 0.11 (7.2) 30 7.26 (7.2) 52.0 % -7.15 [ -10.79, -3.51 ]
Subtotal (95% CI) 155 159 100.0 % -8.30 [ -10.93, -5.67 ]
Heterogeneity: Chi2 = 2.18, df = 3 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 6.19 (P < 0.00001)
4 Children with Volumatic
Batra 1997 30 -12.8 (9.4) 30 -7.4 (11.6) 71.0 % -5.40 [ -10.74, -0.06 ]
Vazquez 1992 9 -10 (10) 9 0 (8) 29.0 % -10.00 [ -18.37, -1.63 ]
Subtotal (95% CI) 39 39 100.0 % -6.73 [ -11.24, -2.23 ]
Heterogeneity: Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 2.93 (P = 0.0034)
Test for subgroup differences: Chi2 = 13.79, df = 3 (P = 0.00), I2 =78%
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A D D I T I O N A L T A B L E S
Table 1. Details of spacers used
Study ID Spacer Type Spacer Volume Adults of Children Number of subjects
Ba 1989 Nebuhaler 750 Children 27
Batra 1997 Volumatic 750 Children 60
Burrows 2004 unknown Children 29
Chong-Neto 2005 Aerochamber and
home made
145 or 500 Children 30
Chou 1995 Aerochamber 145 Children 152
Coker 1995 Volumatic 750 Children 36
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Table 1. Details of spacers used (Continued)
Colacone 1993 Aerochamber 145 Adults 80
Dewar 1999 Volumatic 750 Children 62
Duarte 2002 home made 500 Children 196
Freelander 1984 Nebuhaler 750 Children 28
Hussein 2002 Large volume Children 60
Idris 1993 Inspirease 650 Adults 35
Kerem 1993 Volumatic 750 Children 33
Leversha 2000 Aerochamber 145 Children 60
Lin 1995 Aerochamber 145 Children 111
Maldano 1997 unknown Children 42
Morely 1988 Inspirease 650 Adults 28
Morrone 1990 unknown 500 Adults 44
Parkin 1995 Aerochamber 145 Children 60
Pendergast 1989 Nebuhaler 750 Children 27
Ploin 2000 Babyhaler 350 Children 64
Raimondi 1997 Aerochamber 145 Adults 27
Rao 2002 unknown Adults 50
Robertson 1998 Volumatic 750 Children 155
Rodrigo 1993 Volumatic 750 Adults 97
Rogrigo 1997 Volumatic 750 Adults 22
Rodriguez 1999 Volumatic 750 Adults 69
Salzman 1989 Aerochamber 145 Adults 44
Turner 1988 Inspirease 650 Adults 53
Valencia 1999 home made 500 Children 70
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Table 1. Details of spacers used (Continued)
Vazquez 1992 Volumatic 750 Children 18
Vivek 2003 Nebuhaler 750 Adults 122
Williams 1996 Aerochamber 145 Children 40
WH A T ’ S N E W
Last assessed as up-to-date: 21 July 2008.
Date Event Description
28 July 2008 New search has been performed Converted to new review format and two new studies added (Jamalvi 2006 and
Sannier 2006). No change in conclusions
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 3, 1996
Date Event Description
4 January 2006 New search has been performed For the 2006 update of this review 4 new trials have been added: Burrows 2005
including 29 paediatric in-patients, Chong-Neto 2005 included 30 children
given multiple treatments, Hussein 2002 including 60 children given a single
treatment, Rao 2002 including 50 adults given multiple treatments and Vivek
2003 including 120 patients aged 10-50 (and therefore classified as adult) given
multiple treatments.
An additional table has been added with details of the holding chambers used
in each study, and new comparisons added according to type of chamber. This
was done because Volumatic spacers were no longer being manufactured (but
they have now been reintroduced)
29 July 2003 New search has been performed Three further trials were added to the review in 1999, but the conclusions of the
review remained unchanged. For the 2001 update a further four studies were
added and reduced the confidence intervals around the results.
One open trial in children has been added for the 2003 update (Duarte 2002)
including a further 196 children studied in an emergency room setting in Brazil.
In addition the 2003 update has expanded the review to include trials on in-
patients and five new trials have been added including 184 children and 28
adults (Ba 1989, Coker 1995, Dewar 1999, Morley 1988 and Parkin 1995)
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(Continued)
. The results of the in-patient trials have not been pooled, but are in keeping
with the findings in the emergency room and community setting, that holding
chambers can be as effective as nebulisers for delivery of beta-agonists in acute
asthma
C O N T R I B U T I O N S O F A U T H O R S
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Bara independently assessed trials for inclusion, and extracted trial data for the 1997,1999 and 2001 updates. JAC and CJC assessed
trials for inclusion and extracted data for the 2003 and 2006 update (to include trials on in-patients). CJC and BHR have updated the
review to include further trials in 1997, 1999 and 2001. CJC, JAC and BHR have carried out the 2003, 2006 and 2008 updates.
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